Thanatophoric Dysplasia Type 2

Mendelian MONDO:0008547 Pathograph 8 FGFR3-related skeletal dysplasia Lethal skeletal dysplasia

Thanatophoric dysplasia type 2 (TD2) is a severe, usually lethal skeletal dysplasia caused by the heterozygous FGFR3 K650E (p.Lys650Glu) mutation in the tyrosine kinase domain activation loop. It is distinguished from TD1 by straight (rather than curved) femurs and a high frequency of cloverleaf skull (kleeblattschadel). Like TD1, it features extreme rhizomelic limb shortening, narrow thorax causing pulmonary hypoplasia, platyspondyly, and macrocephaly. The K650E mutation introduces a network of hydrogen bonds that mimic activation-loop tyrosine phosphorylation, locking FGFR3 in its active conformation and constitutively activating downstream STAT and MAPK/ERK signaling. This profoundly inhibits chondrocyte differentiation and proliferation in the growth plate, disrupts endochondral ossification, and causes premature craniosynostosis. Perinatal lethality is typical due to respiratory insufficiency from pulmonary hypoplasia, though rare long-term survivors have been reported with intensive respiratory support. The K650E mutation is genetically homogeneous, being found in all molecularly characterized TD2 cases.

Ask OpenScientist

Ask a research question about Thanatophoric Dysplasia Type 2. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
8
Pathophys.
21
Phenotypes
8
Pathograph
1
Genes
2
Treatments
3
Models
24
References
3
Deep Research
👪

Inheritance

1
Autosomal dominant (de novo)
Virtually all cases arise from de novo heterozygous mutations. The K650E mutation is highly recurrent at a CpG dinucleotide, explaining the consistent genotype in TD2.
Show evidence (1 reference)
PMID:7773297 SUPPORT Human Clinical
"A sporadic mutation causing a Lys650Glu change in the tyrosine kinase domain of FGFR3 was found in 16 of 16 individuals with one type of TD."
All 16 TD2 cases carried the same de novo K650E mutation, confirming the sporadic and genetically homogeneous nature of TD2.
⚙

Pathophysiology

8
Constitutive FGFR3 kinase activation by K650E
The K650E mutation in the FGFR3 tyrosine kinase activation loop introduces a network of intramolecular hydrogen bonds that mimic the structural effect of activation-loop tyrosine phosphorylation, locking the kinase in its active conformation independent of ligand binding or A-loop phosphorylation. Crystal structure analysis shows that the glutamate side chain at position 650 forms hydrogen bonds with the catalytic loop arginine R616 and backbone amides of adjacent residues, stabilizing the active-state A-loop conformation and disengaging the autoinhibitory molecular brake at the kinase hinge region. This constitutive activation is more severe than the K650M mutation (associated with SADDAN syndrome).
FGFR signaling pathway link ↑ INCREASED
Downstream
STAT1/p21-mediated growth plate chondrocyte arrest
Sustained ERK/MAPK pathway activation
PLCgamma-STAT1-mediated chondrocyte apoptosis
Show evidence (2 references)
PMID:23972473 SUPPORT In Vitro
"the mutation introduces a network of intramolecular hydrogen bonds to stabilize the active-state conformation"
Crystal structure of FGFR3 K650E shows the mutation mimics A-loop phosphorylation, providing the structural basis for constitutive activation.
PMID:23972473 SUPPORT In Vitro
"the K650E mutation circumvents the requirement for A-loop tyrosine phosphorylation in kinase activation"
Biochemical and structural analysis demonstrates that K650E confers ligand-independent and phosphorylation-independent kinase activity.
STAT1/p21-mediated growth plate chondrocyte arrest
Constitutively activated FGFR3 K650E signals through STAT1 and STAT5 in growth plate chondrocytes, upregulating the cell cycle inhibitor p21Cip1 and ink4 family members (p16, p18, p19). This drives premature exit of proliferative chondrocytes from the cell cycle and blocks their normal progression to hypertrophic differentiation. The extent of STAT1/p21 overexpression correlates directly with phenotypic severity across the FGFR3-related chondrodysplasia spectrum, being most pronounced in thanatophoric dysplasia.
Growth plate chondrocyte link
JAK-STAT signaling link ↑ INCREASED Negative regulation of cell cycle link ↑ INCREASED Negative regulation of chondrocyte differentiation link ↑ INCREASED
Downstream
Disrupted endochondral ossification via Sox9/beta-catenin dysregulation
Show evidence (3 references)
PMID:14751560 SUPPORT Human Clinical
"Abnormally high amounts of Stat1, Stat5 and p21Cip1 proteins were found in prehypertrophic-hypertrophic chondrocytes, the extent of overexpression being directly related to the severity of the disease."
Direct human fetal growth plate analysis showing severity-correlated STAT/p21 overexpression across ACH and TD, with TD most severe.
PMID:14751560 SUPPORT Human Clinical
"defective differentiation of chondrocytes is the main cause of longitudinal bone growth retardation in FGFR3-related human chondrodysplasias"
Demonstrates that chondrocyte differentiation defect (not proliferation alone) is the primary mechanism.
PMID:9887329 SUPPORT Model Organism
"expression of the mutant receptor caused the activation of Stat1, Stat5a and Stat5b, and the up-regulation of p16, p18 and p19 cell cycle inhibitors, leading to dramatic expansion of the resting zone of chondrocytes at the expense of the proliferating chondrocytes"
Mouse knock-in model with the equivalent K644E mutation directly demonstrates STAT and ink4 upregulation causing growth plate disruption.
Sustained ERK/MAPK pathway activation
The K650E FGFR3 mutation also constitutively activates the RAS/MEK/ERK (MAPK) signaling cascade. Sustained ERK1/2 activation drives premature hypertrophic differentiation of growth plate chondrocytes. Studies in PC12 cells expressing inducible K650E FGFR3 demonstrate that sustained ERK1/2 activation is necessary for the ligand-independent differentiation phenotype, while STAT1/3 activation alone is not sufficient.
MAPK cascade link ↑ INCREASED
Downstream
Disrupted endochondral ossification via Sox9/beta-catenin dysregulation Sustained ERK/MAPK signaling drives premature chondrocyte differentiation and disrupts endochondral ossification.
Premature craniosynostosis and synchondrosis closure FGFR3-MAPK signaling additionally promotes premature synchondrosis closure and cranial suture fusion.
Show evidence (3 references)
PMID:15843401 SUPPORT In Vitro
"sustained activation of ERK1/2 and activation of STAT1 and STAT3, but not STAT5, is observed in the absence of ligand"
PC12 cells expressing the TDII K650E mutation show constitutive ligand-independent ERK1/2 and STAT activation.
PMID:15843401 SUPPORT In Vitro
"Silencing of STAT1 or 3 independently or in combination had no significant effect on ligand-independent neurite outgrowth, ERK1/2 activation or p21(WAF1/CIP1) protein levels"
STAT1/3 knockdown does not block the differentiation phenotype, establishing ERK1/2 as the key pathway for premature differentiation.
PMID:20034074 SUPPORT Other
"The signal transducers and activators of transcription (STAT1) pathway is involved in the inhibition of chondrocyte proliferation, and the mitogen-activated protein kinase (MAPK) pathways are involved in chondrocyte differentiation."
Review article summarizing that STAT1 mediates proliferation inhibition while MAPK mediates differentiation effects in FGFR3 chondrodysplasias.
PLCgamma-STAT1-mediated chondrocyte apoptosis
In addition to cell cycle arrest, the constitutively active FGFR3 K650E promotes premature apoptosis of growth plate chondrocytes. Signaling through phospholipase C gamma (PLCgamma) activates STAT1, which induces caspase- dependent apoptosis. In human TD fetal growth plates, increased apoptotic chondrocytes are associated with elevated Bax and decreased Bcl-2 levels. This apoptotic phenotype compounds the differentiation block to severely reduce the hypertrophic zone required for ossification.
Chondrocyte link
Apoptotic signaling pathway link ↑ INCREASED
Show evidence (3 references)
PMID:9582336 SUPPORT Human Clinical
"the presence of an increased number of apoptotic chondrocytes in TD fetuses was associated with a higher expression of Bax and the simultaneous decrease of Bcl-2 levels"
Direct observation of increased apoptosis with pro-apoptotic Bax/Bcl-2 shift in human TD fetal growth plate chondrocytes.
PMID:9582336 SUPPORT In Vitro
"FGFR 3 mutations in TD I fetuses do not hamper chondrocyte proliferation but rather alter their differentiation by triggering premature apoptosis through activation of the STAT signaling pathway"
Establishes that apoptosis (not proliferation defect) is the primary cellular consequence in TD, mediated by STAT signaling.
PMID:17561467 SUPPORT In Vitro
"the constitutively active forms of FGFR3 (TDII-FGFR3) and STAT1 (STAT1-C) induce apoptosis of chondrogenic ATDC5 cells via caspase activity"
Demonstrates that TDII-FGFR3 specifically induces apoptosis through the PLCgamma-STAT1 pathway in chondrogenic cells.
Disrupted endochondral ossification via Sox9/beta-catenin dysregulation
The FGFR3 K650E mutation disrupts endochondral ossification by stabilizing Sox9 and promoting beta-catenin degradation in growth plate chondrocytes. This creates a block at the prehypertrophic stage, severely reducing the hypertrophic chondrocytes that produce VEGF, which in turn impairs vascularization of primary ossification centers. Since both Sox9 overexpression and beta-catenin deletion independently block hypertrophic differentiation, the simultaneous dysregulation of both constitutes a critical mechanism underlying the skeletal phenotype.
Growth plate chondrocyte link
Endochondral ossification link ↓ DECREASED
Show evidence (3 references)
PMID:22843502 SUPPORT Model Organism
"the mutant receptor caused a block in chondrocyte differentiation specifically at the prehypertrophic stage"
TD2 mouse model shows FGFR3 K650E blocks chondrocyte maturation at the prehypertrophic stage.
PMID:22843502 SUPPORT Model Organism
"the differentiation block and defects in joint formation are associated with persistent expression of the chondrogenic factor Sox9 and down-regulation of β-catenin levels and activity in growth plate chondrocytes"
Identifies Sox9 stabilization and beta-catenin loss as the molecular circuit disrupted by K650E FGFR3 in the TD2 mouse model.
PMID:22843502 SUPPORT Model Organism
"The differentiation block led to a severe reduction in hypertrophic chondrocytes that normally produce vascular endothelial growth factor"
Links the chondrocyte differentiation block to impaired VEGF production and defective ossification center vascularization.
Premature craniosynostosis and synchondrosis closure
The FGFR3 K650E mutation affects cranial suture and synchondrosis development, leading to the cloverleaf skull deformity (kleeblattschadel) seen in most TD2 cases. FGFR3-MAPK signaling in chondrocytes promotes premature synchondrosis closure and fusion of ossification centers in the cranial base and spine by increasing BMP ligand expression and decreasing BMP antagonist expression. This premature closure contributes to foramen magnum stenosis and spinal canal narrowing, which can cause neurological complications. The cloverleaf skull involves premature fusion of multiple cranial sutures with compensatory bulging at patent sutures, and the resulting craniostenosis contributes to intracranial hypertension and pseudoencephaloceles.
Cranial suture morphogenesis link MAPK cascade link ↑ INCREASED
Show evidence (4 references)
PMID:18923003 SUPPORT Model Organism
"FGFR3 and MAPK signaling in chondrocytes promote synchondrosis closure and fusion of ossification centers"
Demonstrates that FGFR3-MAPK drives premature synchondrosis closure in cranial base and spine, directly explaining foramen magnum stenosis.
PMID:18923003 SUPPORT Model Organism
"FGF signaling in chondrocytes increases Bmp ligand mRNA expression and decreases Bmp antagonist mRNA expression in a MAPK-dependent manner"
Identifies BMP pathway modulation as the MAPK-dependent mechanism driving accelerated ossification center fusion.
PMID:18923003 SUPPORT Human Clinical
"premature synchondrosis closure in the spine and cranial base in human cases of homozygous achondroplasia and thanatophoric dysplasia"
Confirms premature synchondrosis closure in human TD cases, not just mouse models.
+ 1 more reference
Pulmonary hypoplasia from thoracic restriction
The severely narrow thorax restricts lung development in utero, resulting in pulmonary hypoplasia that is the primary cause of perinatal death. Respiratory insufficiency from small lung volume relative to body size is the immediate cause of lethality in most cases.
Chondrocyte link
Lung development link ↓ DECREASED
Show evidence (1 reference)
PMID:8845844 SUPPORT Human Clinical
"Thanatophoric dwarfism (TD) is a sporadic lethal skeletal dysplasia with micromelic shortening of the limbs, macrocephaly, platyspondyly and reduced thoracic cavity."
Confirms the reduced thoracic cavity that restricts lung growth and causes the pulmonary hypoplasia responsible for perinatal lethality.
CNS effects of FGFR3 gain-of-function
FGFR3 K650E has direct effects on brain development beyond the secondary consequences of craniosynostosis. In mouse models expressing constitutively active FGFR3 K650E in postmitotic glutamatergic neurons, the mutation disrupts radial glial cell mitosis, inside-out radial migration of cortical neurons, and axonal tract projections. This contributes to the cortical dysplasia and severe developmental delay observed in TD2 survivors.
Axon guidance link
Show evidence (2 references)
PMID:33116259 SUPPORT Model Organism
"GOF disrupts mitosis of radial-glia neural progenitors (RGCs), inside-out radial migration of post-mitotic glutamatergic neurons, and axonal tract projections"
Mouse model expressing FGFR3 K650E in neurons demonstrates direct CNS effects including neuronal migration and axonal guidance defects.
PMID:21204232 SUPPORT Human Clinical
"FGF ligands and receptors (including FGFR3) act in concert to organize the whole telencephalon activity, rather than independently patterning different areas"
FGFR3 has direct roles in telencephalic patterning, supporting the notion that K650E gain-of-function causes primary brain malformations.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Thanatophoric Dysplasia Type 2 Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

21
Head and Neck 4
Cloverleaf skull HP_0040281 Cloverleaf skull (HP:0002676)
Show evidence (2 references)
PMID:3130852 SUPPORT Human Clinical
"Almost all type 2 cases have severe CS."
Direct qualitative frequency evidence supporting a VERY_FREQUENT cloverleaf skull phenotype in TD2.
PMID:8845844 SUPPORT Human Clinical
"in TD2, straight femurs are associated with cloverleaf skull."
Establishes the association of cloverleaf skull with TD2 specifically.
Macrocephaly Macrocephaly (HP:0000256)
Show evidence (2 references)
PMID:24075385 SUPPORT Human Clinical
"The pregnancy was subsequently terminated, and a 480-g malformed fetus was delivered with macrocephaly, depressed nasal bridge, short upturned nasal tip, hypoplastic midface, frontal bossing, short digits, trident-shaped hands, short limbs, cloverleaf skull, narrow chest, brachydactyly, nuchal..."
Molecularly confirmed TD2 case documents macrocephaly among the craniofacial findings.
PMID:8845844 SUPPORT Human Clinical
"Thanatophoric dwarfism (TD) is a sporadic lethal skeletal dysplasia with micromelic shortening of the limbs, macrocephaly, platyspondyly and reduced thoracic cavity."
Confirms macrocephaly as a core TD feature.
Frontal bossing Frontal bossing (HP:0002007)
Show evidence (1 reference)
PMID:24075385 SUPPORT Human Clinical
"The prenatal ultrasound showed short straight femurs, prominent forehead, narrow chest, skin edema, short limbs, and cloverleaf skull consistent with the diagnosis of TD2."
Molecularly confirmed prenatal TD2 case supports frontal bossing/prominent forehead as a craniofacial manifestation.
Small foramen magnum Small foramen magnum (HP:0002677)
Show evidence (1 reference)
PMID:18923003 SUPPORT Human Clinical
"spinal canal and foramen magnum stenosis can cause serious neurologic complications"
Establishes foramen magnum stenosis as a clinically significant feature of FGFR3 chondrodysplasias including TD.
Integument 2
Redundant skin folds Redundant skin (HP:0001582)
Show evidence (1 reference)
PMID:11241532 SUPPORT Human Clinical
"Three-dimensional ultrasound was able to enhance the visualization of thickened, redundant skin folds and craniofacial and limb deformities associated with TD."
Prenatal imaging study documents redundant skin folds as part of the TD fetal phenotype; included here because the same series contains a molecularly confirmed TD2 case.
Acanthosis nigricans (survivors) Acanthosis nigricans (HP:0000956)
Observed in long-term survivors. This skin finding is shared with SADDAN syndrome, which also has an FGFR3 K650 mutation (K650M).
Show evidence (1 reference)
PMID:34597445 SUPPORT Human Clinical
"Skin disorders (acanthosis nigricans and seborrheic keratoses) were common."
Documents acanthosis nigricans in TD long-term survivors, a finding shared with the related FGFR3 K650M SADDAN phenotype.
Limbs 2
Brachydactyly Brachydactyly (HP:0001156)
Show evidence (1 reference)
PMID:24075385 SUPPORT Human Clinical
"The pregnancy was subsequently terminated, and a 480-g malformed fetus was delivered with macrocephaly, depressed nasal bridge, short upturned nasal tip, hypoplastic midface, frontal bossing, short digits, trident-shaped hands, short limbs, cloverleaf skull, narrow chest, brachydactyly, nuchal..."
Molecularly confirmed TD2 case documents short digits and brachydactyly.
Trident hand Trident hand (HP:0004060)
Show evidence (1 reference)
PMID:24075385 SUPPORT Human Clinical
"The pregnancy was subsequently terminated, and a 480-g malformed fetus was delivered with macrocephaly, depressed nasal bridge, short upturned nasal tip, hypoplastic midface, frontal bossing, short digits, trident-shaped hands, short limbs, cloverleaf skull, narrow chest, brachydactyly, nuchal..."
Molecularly confirmed TD2 case explicitly documents trident-shaped hands.
Musculoskeletal 4
Short ribs Short ribs (HP:0000773)
Show evidence (1 reference)
PMID:20301540 SUPPORT Human Clinical
"Other features common to type 1 and type 2 include: short ribs, narrow thorax, relative macrocephaly, distinctive facial features, brachydactyly, hypotonia, and redundant skin folds along the limbs."
GeneReviews explicitly lists short ribs among the features shared by TD1 and TD2, providing stronger subtype-relevant evidence than the prior citation from a non-K650E case introduction.
Narrow thorax Narrow chest (HP:0000774)
Show evidence (2 references)
PMID:11241532 SUPPORT Human Clinical
"The TD2 fetus was characterized by polyhydramnios, short limbs, a narrow thoracic cage, straight short femora, hydrocephalus and a cloverleaf skull at 24 weeks' gestation."
Prenatal case report documenting a narrow thoracic cage in molecularly confirmed TD2.
PMID:8845844 SUPPORT Human Clinical
"Thanatophoric dwarfism (TD) is a sporadic lethal skeletal dysplasia with micromelic shortening of the limbs, macrocephaly, platyspondyly and reduced thoracic cavity."
Confirms reduced thoracic cavity as a core thanatophoric dysplasia feature.
Platyspondyly Platyspondyly (HP:0000926)
Show evidence (1 reference)
PMID:8845844 SUPPORT Human Clinical
"Thanatophoric dwarfism (TD) is a sporadic lethal skeletal dysplasia with micromelic shortening of the limbs, macrocephaly, platyspondyly and reduced thoracic cavity."
Confirms platyspondyly as a core feature.
Hypotonia Hypotonia (HP:0001252)
Show evidence (1 reference)
PMID:20301540 SUPPORT Human Clinical
"Other features common to type 1 and type 2 include: short ribs, narrow thorax, relative macrocephaly, distinctive facial features, brachydactyly, hypotonia, and redundant skin folds along the limbs."
GeneReviews explicitly lists hypotonia among the features shared by TD1 and TD2.
Nervous System 3
Hydrocephalus Hydrocephalus (HP:0000238)
Show evidence (2 references)
PMID:11241532 SUPPORT Human Clinical
"The TD2 fetus was characterized by polyhydramnios, short limbs, a narrow thoracic cage, straight short femora, hydrocephalus and a cloverleaf skull at 24 weeks' gestation."
Molecularly confirmed prenatal TD2 case documents hydrocephalus.
PMID:29458880 SUPPORT Human Clinical
"Fetuses with TD2 may present increased NT, early onset hydrocephalus, enlarged cerebellum and cisterna magna, and hydrancephaly on prenatal ultrasound."
Documents the spectrum of prenatal brain findings in TD2 including early onset hydrocephalus and hydrancephaly.
Temporal lobe dysplasia Temporal lobe dysplasia (HP:0034222)
Show evidence (2 references)
PMID:23323754 SUPPORT Human Clinical
"Temporal lobe dysplasia was recognized in 52% of the cases, and after 1998 temporal lobe dysplasia was described in all cases."
Large autopsy series shows temporal lobe dysplasia is a recurring neuropathologic manifestation of thanatophoric dysplasia.
PMID:11965423 SUPPORT Human Clinical
"Microscopic examination of both cases revealed temporal lobe polymicrogyria, abnormalities of the hippocampus and heterotopic neuroglial tissue within the meninges. There were no noticeable differences in CNS abnormalities between TD type I and II."
Neuropathologic study including one TD2 case supports that the temporal lobe malformation phenotype also occurs in TD2.
Severe global developmental delay Global developmental delay (HP:0001263)
Observed in long-term survivors only; most cases are perinatally lethal.
Show evidence (1 reference)
PMID:34597445 SUPPORT Human Clinical
"All individuals showed severely delayed psychomotor development. The highest level of psychosocial development was equivalent to that at 2 years of age."
Characterizes the developmental ceiling in surviving TD individuals.
Prenatal and Birth 1
Polyhydramnios Polyhydramnios (HP:0001561)
Show evidence (1 reference)
PMID:11241532 SUPPORT Human Clinical
"The TD2 fetus was characterized by polyhydramnios, short limbs, a narrow thoracic cage, straight short femora, hydrocephalus and a cloverleaf skull at 24 weeks' gestation."
Molecularly confirmed prenatal TD2 case documents polyhydramnios.
Respiratory 2
Pulmonary hypoplasia Pulmonary hypoplasia (HP:0002089)
Show evidence (2 references)
PMID:23323754 SUPPORT Human Clinical
"Lung/body, brain/body, and brain/lung weight ratios confirm macrocephaly and lung hypoplasia, which are constant findings in cases involving thanatophoric dysplasia."
Large autopsy series identifies lung hypoplasia as a constant morphologic finding in thanatophoric dysplasia.
PMID:33520059 SUPPORT Human Clinical
"The fetal death is usually due to severe respiratory insufficiency from a reduced thoracic capacity and hypoplastic lungs and/or respiratory failure due to brainstem compression."
Independent case report links pulmonary hypoplasia to the lethal respiratory phenotype.
Respiratory insufficiency Respiratory insufficiency (HP:0002093)
Show evidence (2 references)
PMID:33520059 SUPPORT Human Clinical
"The fetal death is usually due to severe respiratory insufficiency from a reduced thoracic capacity and hypoplastic lungs and/or respiratory failure due to brainstem compression."
Supports respiratory insufficiency as the dominant lethal clinical consequence of the thoracic and pulmonary phenotype.
PMID:34597445 SUPPORT Human Clinical
"All individuals required assisted ventilation."
Study of 20 long-term TD survivors confirms universal requirement for ventilatory support.
Growth 2
Lethal short-limbed short stature Lethal short-limbed short stature (HP:0008909)
Show evidence (1 reference)
PMID:8845844 SUPPORT Human Clinical
"Thanatophoric dwarfism (TD) is a sporadic lethal skeletal dysplasia with micromelic shortening of the limbs, macrocephaly, platyspondyly and reduced thoracic cavity."
Classic clinical description confirming micromelic limb shortening as a defining feature of thanatophoric dysplasia.
Severe short stature (survivors) Short stature (HP:0004322)
Observed in long-term survivors only.
Show evidence (1 reference)
PMID:34597445 SUPPORT Human Clinical
"The mean length at birth was 36 cm (-3.4 SD to -7.9 SD). The adult height (age >16 years) was <-15.2 SD."
Quantifies the extreme growth deficiency in TD survivors.
Other 1
Straight femurs
No specific HPO term currently captures the TD2-defining straight (non-bowed) femur morphology with proximal medial spike. Broader parent terms such as HP:0002823 (Abnormal femur morphology) do not represent the key straight-versus-curved distinction from TD1, so this phenotype is left unbound pending a more precise term.
Show evidence (2 references)
PMID:8845844 SUPPORT Human Clinical
"In the most common subtype (TD1), femurs are curved, while in TD2, straight femurs are associated with cloverleaf skull."
Defines straight femurs as the distinguishing TD2 radiographic feature.
PMID:21204232 SUPPORT Human Clinical
"the femur, which appears curved in TD1, while it remains straight but with a proximal medial spike in TD2"
Adds the proximal medial spike detail for TD2 femur morphology.
🧬

Genetic Associations

1
FGFR3 K650E mutation (Causative)
Show evidence (3 references)
PMID:7773297 SUPPORT Human Clinical
"A sporadic mutation causing a Lys650Glu change in the tyrosine kinase domain of FGFR3 was found in 16 of 16 individuals with one type of TD."
Original identification of the K650E mutation in all 16 TD2 cases.
PMID:8845844 SUPPORT Human Clinical
"While TD2 was accounted for by a single recurrent mutation in the tyrosine kinase 2 domain, TD1 resulted from either stop codon mutations or missense mutations in the extracellular domain of the gene."
Confirms TD2 genetic homogeneity with a single recurrent tyrosine kinase domain mutation, in contrast to TD1 heterogeneity.
PMID:21204232 SUPPORT Human Clinical
"the K650E mutation involving the change of a lysine to glutamic acid ("Lys650Glu") has been found in all TD2 cases to date"
Confirms 100% genotype-phenotype correlation for K650E in TD2.
💊

Treatments

2
Supportive and palliative care
Action: Supportive care Ontology label: supportive care MAXO:0000950
Most affected infants die shortly after birth from respiratory failure. Palliative care is typically provided. Rare long-term survivors require continuous ventilatory support, and some can be transitioned to home-based care with meticulous respiratory and nutritional management. The long-term survivor literature is generally thanatophoric dysplasia-wide and not always subtype-resolved, so survivor management claims should not be read as confirmed TD2-specific unless a report documents the subtype. For survivors, management also includes monitoring and treatment of hydrocephalus, craniocervical junction constriction, seizures, hearing impairment, and developmental complications.
Show evidence (2 references)
PMID:34597445 SUPPORT Human Clinical
"Long-term survival of TD individuals is common. Some individuals enjoy home-based lives; however, they are severely psychosocially and physically disabled and require meticulous respiratory and nutritional support."
Characterizes the intensive supportive care needs of TD long-term survivors, while not establishing that all reported survivors are TD2.
PMID:20301540 SUPPORT Human Clinical
"Other treatment measures may include shunt placement for hydrocephalus, suboccipital decompression for relief of craniocervical junction constriction, anti-seizure medication to control seizures, and hearing aids."
GeneReviews supports the survivor-management details for neurologic, cranial-base, seizure, and hearing complications.
Statin therapy (preclinical)
Action: Statin therapy Ontology label: Pharmacotherapy NCIT:C15986
Statins (lovastatin, rosuvastatin) corrected degraded cartilage formation in TD1 and achondroplasia iPSC-derived chondrocyte models, with additional achondroplasia mouse rescue. This is preclinical FGFR3 chondrodysplasia evidence, not direct TD2 treatment evidence, and there is no clinical application or trial evidence for TD2 newborns.
Show evidence (2 references)
PMID:25231866 SUPPORT In Vitro
"statins could correct the degraded cartilage in both chondrogenically differentiated TD1 and ACH iPSCs."
This supports the in vitro component of the preclinical statin hypothesis, while showing that the patient-derived iPSC evidence is TD1/ACH rather than TD2.
PMID:25231866 SUPPORT Model Organism
"Treatment of ACH model mice with statin led to a significant recovery of bone growth."
This supports additional model-organism preclinical rescue in achondroplasia, not clinical or TD2-specific therapy.
🧫

Experimental Models

3
TD1 and ACH iPSC-derived chondrocytes (statin rescue) IPSC_DERIVED_MODEL
Patient-specific iPSCs from thanatophoric dysplasia type I and achondroplasia patients were differentiated into chondrocytes, recapitulating degraded cartilage formation. Statin treatment corrected the degraded cartilage phenotype in both TD1 and ACH iPSC-derived chondrocytes, suggesting potential therapeutic approaches.
Chondrocyte ↗
Cell source
iPSC
Show evidence (2 references)
PMID:25231866 SUPPORT In Vitro
"The chondrogenic differentiation of TD1 iPSCs and ACH iPSCs resulted in the formation of degraded cartilage"
Patient-derived iPSCs recapitulate the cartilage defect, providing a human cellular model for FGFR3 chondrodysplasias.
PMID:25231866 SUPPORT In Vitro
"statins could correct the degraded cartilage in both chondrogenically differentiated TD1 and ACH iPSCs"
Demonstrates statin-mediated rescue of FGFR3 chondrodysplasia phenotypes in patient-derived iPSC models.
ATDC5 chondrogenic cells expressing TDII-FGFR3 CELL_LINE
ATDC5 chondrogenic cell line expressing the TDII FGFR3 K650E mutation demonstrates constitutive PLCgamma-STAT1 signaling leading to caspase-dependent apoptosis. This model established the PLCgamma-STAT1 apoptotic signaling axis in FGFR3 chondrodysplasia.
Chondrocyte ↗
Cell source
immortalized
Show evidence (1 reference)
PMID:17561467 SUPPORT In Vitro
"the constitutively active forms of FGFR3 (TDII-FGFR3) and STAT1 (STAT1-C) induce apoptosis of chondrogenic ATDC5 cells via caspase activity. DN-PLCgamma reduced the apoptosis of ATDC5 cells expressing TDII-FGFR3"
Identifies PLCgamma as the mediator between FGFR3 K650E and STAT1 activation leading to chondrocyte apoptosis.
PC12 cells expressing inducible K650E FGFR3 CELL_LINE
PC12 cell lines (rat pheochromocytoma) stably expressing inducible FGFR3 with the TDII K650E mutation show sustained ligand-independent ERK1/2 activation and STAT1/3 activation. RNA interference showed that sustained ERK1/2 (not STAT1/3) is required for the differentiation phenotype, establishing the relative contributions of MAPK and STAT pathways.
Chromaffin cell (PC12) ↗
Cell source
immortalized
Show evidence (1 reference)
PMID:15843401 SUPPORT In Vitro
"sustained ERK1/2 activity is required for this ligand-independent differentiation"
Establishes ERK/MAPK as the functionally required pathway for the K650E differentiation phenotype.
{ }

Source YAML

click to show 
name: Thanatophoric Dysplasia Type 2
creation_date: '2026-02-02T00:16:36Z'
updated_date: '2026-04-19T00:32:14Z'
category: Mendelian
description: >
  Thanatophoric dysplasia type 2 (TD2) is a severe, usually lethal skeletal dysplasia
  caused by the heterozygous FGFR3 K650E (p.Lys650Glu) mutation in the tyrosine kinase
  domain activation loop. It is distinguished from TD1 by straight (rather than curved)
  femurs and a high frequency of cloverleaf skull (kleeblattschadel). Like TD1, it
  features extreme rhizomelic limb shortening, narrow thorax causing pulmonary
  hypoplasia, platyspondyly, and macrocephaly. The K650E mutation introduces a network
  of hydrogen bonds that mimic activation-loop tyrosine phosphorylation, locking FGFR3
  in its active conformation and constitutively activating downstream STAT and
  MAPK/ERK signaling. This profoundly inhibits chondrocyte differentiation and
  proliferation in the growth plate, disrupts endochondral ossification, and causes
  premature craniosynostosis. Perinatal lethality is typical due to respiratory
  insufficiency from pulmonary hypoplasia, though rare long-term survivors have been
  reported with intensive respiratory support. The K650E mutation is genetically
  homogeneous, being found in all molecularly characterized TD2 cases.
disease_term:
  preferred_term: thanatophoric dysplasia type 2
  term:
    id: MONDO:0008547
    label: thanatophoric dysplasia type 2
parents:
- FGFR3-related skeletal dysplasia
- Lethal skeletal dysplasia
inheritance:
- name: Autosomal dominant (de novo)
  description: >
    Virtually all cases arise from de novo heterozygous mutations. The K650E mutation
    is highly recurrent at a CpG dinucleotide, explaining the consistent genotype
    in TD2.
  evidence:
  - reference: PMID:7773297
    reference_title: "Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A sporadic mutation causing a Lys650Glu change in the tyrosine kinase domain
      of FGFR3 was found in 16 of 16 individuals with one type of TD.
    explanation: >-
      All 16 TD2 cases carried the same de novo K650E mutation, confirming
      the sporadic and genetically homogeneous nature of TD2.
prevalence:
- population: Global live births (TD2 estimate inferred from overall thanatophoric dysplasia prevalence)
  percentage: Approximately 1 in 70,000 live births
  notes: >-
    Population-based prevalence has been reported for thanatophoric dysplasia
    overall rather than for TD2 separately. The original FGFR3 typing study
    identified the Lys650Glu-defined TD2 subtype in 16 of 55 molecularly
    characterized thanatophoric dysplasia cases, so combining that subtype share
    with overall TD birth-prevalence estimates suggests TD2 is likely on the
    order of about 1 in 70,000 live births, with plausible lower values if the
    US surveillance estimate for TD overall is used instead of the traditional 1
    in 20,000 figure.
  evidence:
  - reference: PMID:7773297
    reference_title: "Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Thanatophoric dysplasia (TD), the most common neonatal lethal skeletal
      dysplasia, affects one out of 20,000 live births.
    explanation: Provides the commonly cited overall live-birth prevalence for thanatophoric dysplasia.
  - reference: PMID:7773297
    reference_title: "Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A sporadic mutation causing a Lys650Glu change in the tyrosine kinase domain
      of FGFR3 was found in 16 of 16 individuals with one type of TD.
    explanation: >-
      The Lys650Glu FGFR3 mutation defines TD2, so this case series supports
      the subtype share used in the note.
  - reference: PMID:18698630
    reference_title: "The population-based prevalence of achondroplasia and thanatophoric dysplasia in selected regions of the US."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The prevalence of thanatophoric dysplasia ranged from 0.21 to 0.30 per
      10,000 livebirths (1/33,330-1/47,620 livebirths).
    explanation: >-
      Population-based US surveillance confirms the rarity of thanatophoric
      dysplasia overall and bounds the inferred TD2 estimate.
pathophysiology:
- name: Constitutive FGFR3 kinase activation by K650E
  conforms_to: "fgfr_gain_of_function_skeletal_dysplasia#Constitutive FGFR Activation"
  description: >
    The K650E mutation in the FGFR3 tyrosine kinase activation loop introduces a
    network of intramolecular hydrogen bonds that mimic the structural effect of
    activation-loop tyrosine phosphorylation, locking the kinase in its active
    conformation independent of ligand binding or A-loop phosphorylation. Crystal
    structure analysis shows that the glutamate side chain at position 650 forms
    hydrogen bonds with the catalytic loop arginine R616 and backbone amides of
    adjacent residues, stabilizing the active-state A-loop conformation and
    disengaging the autoinhibitory molecular brake at the kinase hinge region.
    This constitutive activation is more severe than the K650M mutation
    (associated with SADDAN syndrome).
  gene:
    preferred_term: FGFR3
    description: >-
      Fibroblast growth factor receptor 3 with severe gain-of-function mutation
      (K650E) in the kinase domain activation loop.
    modifier: INCREASED
    term:
      id: hgnc:3690
      label: FGFR3
  biological_processes:
  - preferred_term: FGFR signaling pathway
    term:
      id: GO:0008543
      label: fibroblast growth factor receptor signaling pathway
    modifier: INCREASED
  downstream:
  - target: STAT1/p21-mediated growth plate chondrocyte arrest
  - target: Sustained ERK/MAPK pathway activation
  - target: PLCgamma-STAT1-mediated chondrocyte apoptosis
  evidence:
  - reference: PMID:23972473
    reference_title: "Structural mimicry of a-loop tyrosine phosphorylation by a pathogenic FGF receptor 3 mutation."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      the mutation introduces a network of intramolecular hydrogen bonds to
      stabilize the active-state conformation
    explanation: >-
      Crystal structure of FGFR3 K650E shows the mutation mimics A-loop
      phosphorylation, providing the structural basis for constitutive
      activation.
  - reference: PMID:23972473
    reference_title: "Structural mimicry of a-loop tyrosine phosphorylation by a pathogenic FGF receptor 3 mutation."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      the K650E mutation circumvents the requirement for A-loop tyrosine
      phosphorylation in kinase activation
    explanation: >-
      Biochemical and structural analysis demonstrates that K650E confers
      ligand-independent and phosphorylation-independent kinase activity.
- name: STAT1/p21-mediated growth plate chondrocyte arrest
  description: >
    Constitutively activated FGFR3 K650E signals through STAT1 and STAT5 in growth
    plate chondrocytes, upregulating the cell cycle inhibitor p21Cip1 and ink4 family
    members (p16, p18, p19). This drives premature exit of proliferative chondrocytes
    from the cell cycle and blocks their normal progression to hypertrophic
    differentiation. The extent of STAT1/p21 overexpression correlates directly
    with phenotypic severity across the FGFR3-related chondrodysplasia spectrum,
    being most pronounced in thanatophoric dysplasia.
  cell_types:
  - preferred_term: Growth plate chondrocyte
    term:
      id: CL:1000217
      label: growth plate cartilage chondrocyte
  biological_processes:
  - preferred_term: JAK-STAT signaling
    term:
      id: GO:0007259
      label: cell surface receptor signaling pathway via JAK-STAT
    modifier: INCREASED
  - preferred_term: Negative regulation of cell cycle
    term:
      id: GO:0045786
      label: negative regulation of cell cycle
    modifier: INCREASED
  - preferred_term: Negative regulation of chondrocyte differentiation
    term:
      id: GO:0032331
      label: negative regulation of chondrocyte differentiation
    modifier: INCREASED
  downstream:
  - target: Disrupted endochondral ossification via Sox9/beta-catenin dysregulation
  evidence:
  - reference: PMID:14751560
    reference_title: "Overexpression of FGFR3, Stat1, Stat5 and p21Cip1 correlates with phenotypic severity and defective chondrocyte differentiation in FGFR3-related chondrodysplasias."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Abnormally high amounts of Stat1, Stat5 and p21Cip1 proteins were found in
      prehypertrophic-hypertrophic chondrocytes, the extent of overexpression being
      directly related to the severity of the disease.
    explanation: >-
      Direct human fetal growth plate analysis showing severity-correlated
      STAT/p21 overexpression across ACH and TD, with TD most severe.
  - reference: PMID:14751560
    reference_title: "Overexpression of FGFR3, Stat1, Stat5 and p21Cip1 correlates with phenotypic severity and defective chondrocyte differentiation in FGFR3-related chondrodysplasias."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      defective differentiation of chondrocytes is the main cause of longitudinal
      bone growth retardation in FGFR3-related human chondrodysplasias
    explanation: >-
      Demonstrates that chondrocyte differentiation defect (not proliferation
      alone) is the primary mechanism.
  - reference: PMID:9887329
    reference_title: "A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      expression of the mutant receptor caused the activation of Stat1, Stat5a
      and Stat5b, and the up-regulation of p16, p18 and p19 cell cycle
      inhibitors, leading to dramatic expansion of the resting zone of
      chondrocytes at the expense of the proliferating chondrocytes
    explanation: >-
      Mouse knock-in model with the equivalent K644E mutation directly
      demonstrates STAT and ink4 upregulation causing growth plate disruption.
- name: Sustained ERK/MAPK pathway activation
  conforms_to: "fgfr_gain_of_function_skeletal_dysplasia#Sustained MAPK/STAT Signaling"
  description: >
    The K650E FGFR3 mutation also constitutively activates the RAS/MEK/ERK
    (MAPK) signaling cascade. Sustained ERK1/2 activation drives premature
    hypertrophic differentiation of growth plate chondrocytes. Studies in PC12
    cells expressing inducible K650E FGFR3 demonstrate that sustained ERK1/2
    activation is necessary for the ligand-independent differentiation phenotype,
    while STAT1/3 activation alone is not sufficient.
  biological_processes:
  - preferred_term: MAPK cascade
    term:
      id: GO:0000165
      label: MAPK cascade
    modifier: INCREASED
  evidence:
  - reference: PMID:15843401
    reference_title: "Sustained ERK1/2 but not STAT1 or 3 activation is required for thanatophoric dysplasia phenotypes in PC12 cells."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      sustained activation of ERK1/2 and activation of STAT1 and STAT3, but not
      STAT5, is observed in the absence of ligand
    explanation: >-
      PC12 cells expressing the TDII K650E mutation show constitutive
      ligand-independent ERK1/2 and STAT activation.
  - reference: PMID:15843401
    reference_title: "Sustained ERK1/2 but not STAT1 or 3 activation is required for thanatophoric dysplasia phenotypes in PC12 cells."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Silencing of STAT1 or 3 independently or in combination had no significant
      effect on ligand-independent neurite outgrowth, ERK1/2 activation or
      p21(WAF1/CIP1) protein levels
    explanation: >-
      STAT1/3 knockdown does not block the differentiation phenotype,
      establishing ERK1/2 as the key pathway for premature differentiation.
  - reference: PMID:20034074
    reference_title: "Review of the recently defined molecular mechanisms underlying thanatophoric dysplasia and their potential therapeutic implications for achondroplasia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The signal transducers and activators of transcription (STAT1) pathway is
      involved in the inhibition of chondrocyte proliferation, and the
      mitogen-activated protein kinase (MAPK) pathways are involved in
      chondrocyte differentiation.
    explanation: >-
      Review article summarizing that STAT1 mediates proliferation inhibition
      while MAPK mediates differentiation effects in FGFR3 chondrodysplasias.
  downstream:
  - target: Disrupted endochondral ossification via Sox9/beta-catenin dysregulation
    description: >-
      Sustained ERK/MAPK signaling drives premature chondrocyte differentiation
      and disrupts endochondral ossification.
    causal_link_type: DIRECT
  - target: Premature craniosynostosis and synchondrosis closure
    description: >-
      FGFR3-MAPK signaling additionally promotes premature synchondrosis closure
      and cranial suture fusion.
    causal_link_type: DIRECT
- name: PLCgamma-STAT1-mediated chondrocyte apoptosis
  description: >
    In addition to cell cycle arrest, the constitutively active FGFR3 K650E
    promotes premature apoptosis of growth plate chondrocytes. Signaling through
    phospholipase C gamma (PLCgamma) activates STAT1, which induces caspase-
    dependent apoptosis. In human TD fetal growth plates, increased apoptotic
    chondrocytes are associated with elevated Bax and decreased Bcl-2 levels.
    This apoptotic phenotype compounds the differentiation block to severely
    reduce the hypertrophic zone required for ossification.
  cell_types:
  - preferred_term: Chondrocyte
    term:
      id: CL:0000138
      label: chondrocyte
  biological_processes:
  - preferred_term: Apoptotic signaling pathway
    term:
      id: GO:0097190
      label: apoptotic signaling pathway
    modifier: INCREASED
  evidence:
  - reference: PMID:9582336
    reference_title: "Fibroblast growth factor receptor 3 mutations promote apoptosis but do not alter chondrocyte proliferation in thanatophoric dysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the presence of an increased number of apoptotic chondrocytes in TD fetuses
      was associated with a higher expression of Bax and the simultaneous decrease
      of Bcl-2 levels
    explanation: >-
      Direct observation of increased apoptosis with pro-apoptotic Bax/Bcl-2
      shift in human TD fetal growth plate chondrocytes.
  - reference: PMID:9582336
    reference_title: "Fibroblast growth factor receptor 3 mutations promote apoptosis but do not alter chondrocyte proliferation in thanatophoric dysplasia."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      FGFR 3 mutations in TD I fetuses do not hamper chondrocyte proliferation
      but rather alter their differentiation by triggering premature apoptosis
      through activation of the STAT signaling pathway
    explanation: >-
      Establishes that apoptosis (not proliferation defect) is the primary
      cellular consequence in TD, mediated by STAT signaling.
  - reference: PMID:17561467
    reference_title: "Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via PLCgamma-activated STAT1."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      the constitutively active forms of FGFR3 (TDII-FGFR3) and STAT1 (STAT1-C)
      induce apoptosis of chondrogenic ATDC5 cells via caspase activity
    explanation: >-
      Demonstrates that TDII-FGFR3 specifically induces apoptosis through
      the PLCgamma-STAT1 pathway in chondrogenic cells.
- name: Disrupted endochondral ossification via Sox9/beta-catenin dysregulation
  conforms_to: "fgfr_gain_of_function_skeletal_dysplasia#Impaired Endochondral Ossification and Chondrodysplasia"
  description: >
    The FGFR3 K650E mutation disrupts endochondral ossification by stabilizing
    Sox9 and promoting beta-catenin degradation in growth plate chondrocytes.
    This creates a block at the prehypertrophic stage, severely reducing the
    hypertrophic chondrocytes that produce VEGF, which in turn impairs
    vascularization of primary ossification centers. Since both Sox9
    overexpression and beta-catenin deletion independently block hypertrophic
    differentiation, the simultaneous dysregulation of both constitutes a
    critical mechanism underlying the skeletal phenotype.
  cell_types:
  - preferred_term: Growth plate chondrocyte
    term:
      id: CL:1000217
      label: growth plate cartilage chondrocyte
  biological_processes:
  - preferred_term: Endochondral ossification
    term:
      id: GO:0001958
      label: endochondral ossification
    modifier: DECREASED
  evidence:
  - reference: PMID:22843502
    reference_title: "Disruption of a Sox9-β-catenin circuit by mutant Fgfr3 in thanatophoric dysplasia type II."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      the mutant receptor caused a block in chondrocyte differentiation
      specifically at the prehypertrophic stage
    explanation: >-
      TD2 mouse model shows FGFR3 K650E blocks chondrocyte maturation at
      the prehypertrophic stage.
  - reference: PMID:22843502
    reference_title: "Disruption of a Sox9-β-catenin circuit by mutant Fgfr3 in thanatophoric dysplasia type II."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      the differentiation block and defects in joint formation are associated
      with persistent expression of the chondrogenic factor Sox9 and
      down-regulation of β-catenin levels and activity in growth plate
      chondrocytes
    explanation: >-
      Identifies Sox9 stabilization and beta-catenin loss as the molecular
      circuit disrupted by K650E FGFR3 in the TD2 mouse model.
  - reference: PMID:22843502
    reference_title: "Disruption of a Sox9-β-catenin circuit by mutant Fgfr3 in thanatophoric dysplasia type II."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      The differentiation block led to a severe reduction in hypertrophic
      chondrocytes that normally produce vascular endothelial growth factor
    explanation: >-
      Links the chondrocyte differentiation block to impaired VEGF production
      and defective ossification center vascularization.
- name: Premature craniosynostosis and synchondrosis closure
  conforms_to: "fgfr_gain_of_function_skeletal_dysplasia#Premature Suture Fusion and Craniosynostosis"
  description: >
    The FGFR3 K650E mutation affects cranial suture and synchondrosis development,
    leading to the cloverleaf skull deformity (kleeblattschadel) seen in most TD2
    cases. FGFR3-MAPK signaling in chondrocytes promotes premature synchondrosis
    closure and fusion of ossification centers in the cranial base and spine by
    increasing BMP ligand expression and decreasing BMP antagonist expression.
    This premature closure contributes to foramen magnum stenosis and spinal canal
    narrowing, which can cause neurological complications. The cloverleaf skull
    involves premature fusion of multiple cranial sutures with compensatory
    bulging at patent sutures, and the resulting craniostenosis contributes to
    intracranial hypertension and pseudoencephaloceles.
  biological_processes:
  - preferred_term: Cranial suture morphogenesis
    term:
      id: GO:0060363
      label: cranial suture morphogenesis
  - preferred_term: MAPK cascade
    term:
      id: GO:0000165
      label: MAPK cascade
    modifier: INCREASED
  evidence:
  - reference: PMID:18923003
    reference_title: "FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      FGFR3 and MAPK signaling in chondrocytes promote synchondrosis closure
      and fusion of ossification centers
    explanation: >-
      Demonstrates that FGFR3-MAPK drives premature synchondrosis closure
      in cranial base and spine, directly explaining foramen magnum stenosis.
  - reference: PMID:18923003
    reference_title: "FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      FGF signaling in chondrocytes increases Bmp ligand mRNA expression and
      decreases Bmp antagonist mRNA expression in a MAPK-dependent manner
    explanation: >-
      Identifies BMP pathway modulation as the MAPK-dependent mechanism
      driving accelerated ossification center fusion.
  - reference: PMID:18923003
    reference_title: "FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      premature synchondrosis closure in the spine and cranial base in human
      cases of homozygous achondroplasia and thanatophoric dysplasia
    explanation: >-
      Confirms premature synchondrosis closure in human TD cases, not
      just mouse models.
  - reference: PMID:21204232
    reference_title: "Thanatophoric dysplasia type II with encephalocele and semilobar holoprosencephaly: Insights into its pathogenesis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      we consider encephaloceles described in TD to be pseudoencephaloceles,
      since they are secondary to the intracranial pressure generated by severe
      hydrocephaly and to severe cranial structural anomalies
    explanation: >-
      Clarifies that brain herniation in TD2 results from intracranial
      pressure due to craniosynostosis and hydrocephalus.
- name: Pulmonary hypoplasia from thoracic restriction
  description: >
    The severely narrow thorax restricts lung development in utero, resulting in
    pulmonary hypoplasia that is the primary cause of perinatal death. Respiratory
    insufficiency from small lung volume relative to body size is the immediate
    cause of lethality in most cases.
  cell_types:
  - preferred_term: Chondrocyte
    term:
      id: CL:0000138
      label: chondrocyte
  biological_processes:
  - preferred_term: Lung development
    term:
      id: GO:0030324
      label: lung development
    modifier: DECREASED
  evidence:
  - reference: PMID:8845844
    reference_title: "Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Thanatophoric dwarfism (TD) is a sporadic lethal skeletal dysplasia with
      micromelic shortening of the limbs, macrocephaly, platyspondyly and reduced
      thoracic cavity.
    explanation: >-
      Confirms the reduced thoracic cavity that restricts lung growth and
      causes the pulmonary hypoplasia responsible for perinatal lethality.
- name: CNS effects of FGFR3 gain-of-function
  description: >
    FGFR3 K650E has direct effects on brain development beyond the secondary
    consequences of craniosynostosis. In mouse models expressing constitutively
    active FGFR3 K650E in postmitotic glutamatergic neurons, the mutation
    disrupts radial glial cell mitosis, inside-out radial migration of cortical
    neurons, and axonal tract projections. This contributes to the cortical
    dysplasia and severe developmental delay observed in TD2 survivors.
  biological_processes:
  - preferred_term: Axon guidance
    term:
      id: GO:0007411
      label: axon guidance
  evidence:
  - reference: PMID:33116259
    reference_title: "Enhanced FGFR3 activity in postmitotic principal neurons during brain development results in cortical dysplasia and axonal tract abnormality."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      GOF disrupts mitosis of radial-glia neural progenitors (RGCs), inside-out
      radial migration of post-mitotic glutamatergic neurons, and axonal tract
      projections
    explanation: >-
      Mouse model expressing FGFR3 K650E in neurons demonstrates direct
      CNS effects including neuronal migration and axonal guidance defects.
  - reference: PMID:21204232
    reference_title: "Thanatophoric dysplasia type II with encephalocele and semilobar holoprosencephaly: Insights into its pathogenesis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      FGF ligands and receptors (including FGFR3) act in concert to organize
      the whole telencephalon activity, rather than independently patterning
      different areas
    explanation: >-
      FGFR3 has direct roles in telencephalic patterning, supporting the
      notion that K650E gain-of-function causes primary brain malformations.
phenotypes:
- name: Lethal short-limbed short stature
  description: >
    Severe micromelia with marked shortening of the limbs, especially
    proximally.
  phenotype_term:
    preferred_term: Lethal short-limbed short stature
    term:
      id: HP:0008909
      label: Lethal short-limbed short stature
  evidence:
  - reference: PMID:8845844
    reference_title: "Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Thanatophoric dwarfism (TD) is a sporadic lethal skeletal dysplasia with
      micromelic shortening of the limbs, macrocephaly, platyspondyly and reduced
      thoracic cavity.
    explanation: >-
      Classic clinical description confirming micromelic limb shortening
      as a defining feature of thanatophoric dysplasia.
- name: Straight femurs
  description: >
    Unlike TD1, the femurs in TD2 are straight rather than bowed. This is the
    key distinguishing radiographic feature between the two types, with TD2
    femurs described as having a proximal medial spike.
  notes: >-
    No specific HPO term currently captures the TD2-defining straight
    (non-bowed) femur morphology with proximal medial spike. Broader parent
    terms such as HP:0002823 (Abnormal femur morphology) do not represent the
    key straight-versus-curved distinction from TD1, so this phenotype is left
    unbound pending a more precise term.
  phenotype_term:
    preferred_term: Straight femur
  evidence:
  - reference: PMID:8845844
    reference_title: "Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In the most common subtype (TD1), femurs are curved, while in TD2, straight
      femurs are associated with cloverleaf skull.
    explanation: >-
      Defines straight femurs as the distinguishing TD2 radiographic feature.
  - reference: PMID:21204232
    reference_title: "Thanatophoric dysplasia type II with encephalocele and semilobar holoprosencephaly: Insights into its pathogenesis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the femur, which appears curved in TD1, while it remains straight but with
      a proximal medial spike in TD2
    explanation: >-
      Adds the proximal medial spike detail for TD2 femur morphology.
- name: Cloverleaf skull
  description: >
    Severe kleeblattschadel with a trilobed skull contour. This is one of the
    most characteristic cranial manifestations of TD2 and helps distinguish it
    from TD1.
  frequency: HP_0040281
  phenotype_term:
    preferred_term: Cloverleaf skull
    term:
      id: HP:0002676
      label: Cloverleaf skull
  evidence:
  - reference: PMID:3130852
    reference_title: "Thanatophoric dysplasia and cloverleaf skull."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Almost all type 2 cases have severe CS.
    explanation: >-
      Direct qualitative frequency evidence supporting a VERY_FREQUENT
      cloverleaf skull phenotype in TD2.
  - reference: PMID:8845844
    reference_title: "Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      in TD2, straight femurs are associated with cloverleaf skull.
    explanation: >-
      Establishes the association of cloverleaf skull with TD2 specifically.
- name: Short ribs
  description: >
    Short ribs contribute to the narrow thorax and secondary pulmonary
    hypoplasia.
  phenotype_term:
    preferred_term: Short ribs
    term:
      id: HP:0000773
      label: Short ribs
  evidence:
  - reference: PMID:20301540
    reference_title: "Thanatophoric Dysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Other features common to type 1 and type 2 include: short ribs, narrow thorax,
      relative macrocephaly, distinctive facial features, brachydactyly, hypotonia,
      and redundant skin folds along the limbs.
    explanation: >-
      GeneReviews explicitly lists short ribs among the features shared by TD1
      and TD2, providing stronger subtype-relevant evidence than the prior
      citation from a non-K650E case introduction.
- name: Narrow thorax
  description: >
    Severely narrow thorax present prenatally and persisting postnatally.
  phenotype_term:
    preferred_term: Narrow chest
    term:
      id: HP:0000774
      label: Narrow chest
  evidence:
  - reference: PMID:11241532
    reference_title: "Prenatal diagnosis and genetic analysis of type I and type II thanatophoric dysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The TD2 fetus was characterized by polyhydramnios, short limbs, a narrow
      thoracic cage, straight short femora, hydrocephalus and a cloverleaf skull
      at 24 weeks' gestation.
    explanation: >-
      Prenatal case report documenting a narrow thoracic cage in molecularly
      confirmed TD2.
  - reference: PMID:8845844
    reference_title: "Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Thanatophoric dwarfism (TD) is a sporadic lethal skeletal dysplasia with
      micromelic shortening of the limbs, macrocephaly, platyspondyly and reduced
      thoracic cavity.
    explanation: Confirms reduced thoracic cavity as a core thanatophoric dysplasia feature.
- name: Pulmonary hypoplasia
  description: >
    Underdevelopment of the lungs secondary to thoracic restriction, contributing
    directly to perinatal lethality.
  phenotype_term:
    preferred_term: Pulmonary hypoplasia
    term:
      id: HP:0002089
      label: Pulmonary hypoplasia
  evidence:
  - reference: PMID:23323754
    reference_title: "Thanatophoric dysplasia: autopsy findings over a 25-year period."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Lung/body, brain/body, and brain/lung weight ratios confirm macrocephaly
      and lung hypoplasia, which are constant findings in cases involving
      thanatophoric dysplasia.
    explanation: >-
      Large autopsy series identifies lung hypoplasia as a constant morphologic
      finding in thanatophoric dysplasia.
  - reference: PMID:33520059
    reference_title: "Thanatophoric dysplasia: a case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The fetal death is usually due to severe respiratory insufficiency from a
      reduced thoracic capacity and hypoplastic lungs and/or respiratory failure
      due to brainstem compression.
    explanation: >-
      Independent case report links pulmonary hypoplasia to the lethal
      respiratory phenotype.
- name: Platyspondyly
  description: Severe flattening of the vertebral bodies.
  phenotype_term:
    preferred_term: Platyspondyly
    term:
      id: HP:0000926
      label: Platyspondyly
  evidence:
  - reference: PMID:8845844
    reference_title: "Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Thanatophoric dwarfism (TD) is a sporadic lethal skeletal dysplasia with
      micromelic shortening of the limbs, macrocephaly, platyspondyly and reduced
      thoracic cavity.
    explanation: Confirms platyspondyly as a core feature.
- name: Macrocephaly
  description: Large head circumference relative to body size.
  phenotype_term:
    preferred_term: Macrocephaly
    term:
      id: HP:0000256
      label: Macrocephaly
  evidence:
  - reference: PMID:24075385
    reference_title: "Rapid detection of K650E mutation in FGFR3 using uncultured amniocytes in a pregnancy affected with fetal cloverleaf skull, occipital pseudoencephalocele, ventriculomegaly, straight short femurs, and thanatophoric dysplasia type II."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The pregnancy was subsequently terminated, and a 480-g malformed fetus was
      delivered with macrocephaly, depressed nasal bridge, short upturned nasal
      tip, hypoplastic midface, frontal bossing, short digits, trident-shaped
      hands, short limbs, cloverleaf skull, narrow chest, brachydactyly, nuchal
      edema, and bulging occipital bone.
    explanation: >-
      Molecularly confirmed TD2 case documents macrocephaly among the craniofacial
      findings.
  - reference: PMID:8845844
    reference_title: "Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Thanatophoric dwarfism (TD) is a sporadic lethal skeletal dysplasia with
      micromelic shortening of the limbs, macrocephaly, platyspondyly and reduced
      thoracic cavity.
    explanation: Confirms macrocephaly as a core TD feature.
- name: Frontal bossing
  description: Prominent forehead.
  phenotype_term:
    preferred_term: Frontal bossing
    term:
      id: HP:0002007
      label: Frontal bossing
  evidence:
  - reference: PMID:24075385
    reference_title: "Rapid detection of K650E mutation in FGFR3 using uncultured amniocytes in a pregnancy affected with fetal cloverleaf skull, occipital pseudoencephalocele, ventriculomegaly, straight short femurs, and thanatophoric dysplasia type II."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The prenatal ultrasound showed short straight femurs, prominent forehead,
      narrow chest, skin edema, short limbs, and cloverleaf skull consistent
      with the diagnosis of TD2.
    explanation: >-
      Molecularly confirmed prenatal TD2 case supports frontal bossing/prominent
      forehead as a craniofacial manifestation.
- name: Brachydactyly
  description: Short digits of the hands and feet.
  phenotype_term:
    preferred_term: Brachydactyly
    term:
      id: HP:0001156
      label: Brachydactyly
  evidence:
  - reference: PMID:24075385
    reference_title: "Rapid detection of K650E mutation in FGFR3 using uncultured amniocytes in a pregnancy affected with fetal cloverleaf skull, occipital pseudoencephalocele, ventriculomegaly, straight short femurs, and thanatophoric dysplasia type II."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The pregnancy was subsequently terminated, and a 480-g malformed fetus was
      delivered with macrocephaly, depressed nasal bridge, short upturned nasal
      tip, hypoplastic midface, frontal bossing, short digits, trident-shaped
      hands, short limbs, cloverleaf skull, narrow chest, brachydactyly, nuchal
      edema, and bulging occipital bone.
    explanation: >-
      Molecularly confirmed TD2 case documents short digits and brachydactyly.
- name: Trident hand
  description: >
    Characteristic hand configuration with short fingers and increased spacing
    between the digits, producing a trident appearance.
  phenotype_term:
    preferred_term: Trident hand
    term:
      id: HP:0004060
      label: Trident hand
  evidence:
  - reference: PMID:24075385
    reference_title: "Rapid detection of K650E mutation in FGFR3 using uncultured amniocytes in a pregnancy affected with fetal cloverleaf skull, occipital pseudoencephalocele, ventriculomegaly, straight short femurs, and thanatophoric dysplasia type II."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The pregnancy was subsequently terminated, and a 480-g malformed fetus was
      delivered with macrocephaly, depressed nasal bridge, short upturned nasal
      tip, hypoplastic midface, frontal bossing, short digits, trident-shaped
      hands, short limbs, cloverleaf skull, narrow chest, brachydactyly, nuchal
      edema, and bulging occipital bone.
    explanation: >-
      Molecularly confirmed TD2 case explicitly documents trident-shaped hands.
- name: Hypotonia
  description: >
    Decreased muscle tone is reported among the clinical features shared by TD1
    and TD2.
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: PMID:20301540
    reference_title: "Thanatophoric Dysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Other features common to type 1 and type 2 include: short ribs, narrow thorax,
      relative macrocephaly, distinctive facial features, brachydactyly, hypotonia,
      and redundant skin folds along the limbs.
    explanation: >-
      GeneReviews explicitly lists hypotonia among the features shared by TD1
      and TD2.
- name: Respiratory insufficiency
  description: >
    Severe respiratory failure is typical in the perinatal period, and long-term
    survivors require ongoing ventilatory support.
  phenotype_term:
    preferred_term: Respiratory insufficiency
    term:
      id: HP:0002093
      label: Respiratory insufficiency
  evidence:
  - reference: PMID:33520059
    reference_title: "Thanatophoric dysplasia: a case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The fetal death is usually due to severe respiratory insufficiency from a
      reduced thoracic capacity and hypoplastic lungs and/or respiratory failure
      due to brainstem compression.
    explanation: >-
      Supports respiratory insufficiency as the dominant lethal clinical
      consequence of the thoracic and pulmonary phenotype.
  - reference: PMID:34597445
    reference_title: "Development of individuals with thanatophoric dysplasia surviving beyond infancy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: All individuals required assisted ventilation.
    explanation: >-
      Study of 20 long-term TD survivors confirms universal requirement for
      ventilatory support.
- name: Hydrocephalus
  description: >
    Prenatal ventricular enlargement and hydrocephalus are reported in some
    TD2 fetuses, and severe fluid-space abnormalities such as hydrancephaly have
    also been described.
  phenotype_term:
    preferred_term: Hydrocephalus
    term:
      id: HP:0000238
      label: Hydrocephalus
  evidence:
  - reference: PMID:11241532
    reference_title: "Prenatal diagnosis and genetic analysis of type I and type II thanatophoric dysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The TD2 fetus was characterized by polyhydramnios, short limbs, a narrow
      thoracic cage, straight short femora, hydrocephalus and a cloverleaf skull
      at 24 weeks' gestation.
    explanation: >-
      Molecularly confirmed prenatal TD2 case documents hydrocephalus.
  - reference: PMID:29458880
    reference_title: "Prenatal diagnosis of hydrancephaly and enlarged cerebellum and cisterna magna in a fetus with thanatophoric dysplasia type II and a review of prenatal diagnosis of brain anomalies associated with thanatophoric dysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Fetuses with TD2 may present increased NT, early onset hydrocephalus,
      enlarged cerebellum and cisterna magna, and hydrancephaly on prenatal
      ultrasound.
    explanation: >-
      Documents the spectrum of prenatal brain findings in TD2 including
      early onset hydrocephalus and hydrancephaly.
- name: Small foramen magnum
  description: >
    Foramen magnum narrowing is a recognized complication of FGFR3-related
    chondrodysplasias and may contribute to cervicomedullary compression in
    surviving individuals.
  phenotype_term:
    preferred_term: Small foramen magnum
    term:
      id: HP:0002677
      label: Small foramen magnum
  evidence:
  - reference: PMID:18923003
    reference_title: "FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      spinal canal and foramen magnum stenosis can cause serious neurologic
      complications
    explanation: >-
      Establishes foramen magnum stenosis as a clinically significant
      feature of FGFR3 chondrodysplasias including TD.
- name: Temporal lobe dysplasia
  description: >
    Intrinsic cerebral malformation involving the temporal lobes, often with
    associated polymicrogyria and hippocampal abnormalities on neuropathologic
    examination.
  phenotype_term:
    preferred_term: Temporal lobe dysplasia
    term:
      id: HP:0034222
      label: Temporal lobe dysplasia
  evidence:
  - reference: PMID:23323754
    reference_title: "Thanatophoric dysplasia: autopsy findings over a 25-year period."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Temporal lobe dysplasia was recognized in 52% of the cases, and after
      1998 temporal lobe dysplasia was described in all cases.
    explanation: >-
      Large autopsy series shows temporal lobe dysplasia is a recurring
      neuropathologic manifestation of thanatophoric dysplasia.
  - reference: PMID:11965423
    reference_title: "[Thanatophoric dysplasia: report of 2 cases with neuropathological study]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Microscopic examination of both cases revealed temporal lobe
      polymicrogyria, abnormalities of the hippocampus and heterotopic
      neuroglial tissue within the meninges. There were no noticeable
      differences in CNS abnormalities between TD type I and II.
    explanation: >-
      Neuropathologic study including one TD2 case supports that the temporal
      lobe malformation phenotype also occurs in TD2.
- name: Polyhydramnios
  description: >
    Excess amniotic fluid can be part of the prenatal presentation of TD2.
  phenotype_term:
    preferred_term: Polyhydramnios
    term:
      id: HP:0001561
      label: Polyhydramnios
  evidence:
  - reference: PMID:11241532
    reference_title: "Prenatal diagnosis and genetic analysis of type I and type II thanatophoric dysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The TD2 fetus was characterized by polyhydramnios, short limbs, a narrow
      thoracic cage, straight short femora, hydrocephalus and a cloverleaf skull
      at 24 weeks' gestation.
    explanation: >-
      Molecularly confirmed prenatal TD2 case documents polyhydramnios.
- name: Redundant skin folds
  description: >
    Thickened redundant skin folds can be appreciated on prenatal imaging.
  phenotype_term:
    preferred_term: Redundant skin
    term:
      id: HP:0001582
      label: Redundant skin
  evidence:
  - reference: PMID:11241532
    reference_title: "Prenatal diagnosis and genetic analysis of type I and type II thanatophoric dysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Three-dimensional ultrasound was able to enhance the visualization of
      thickened, redundant skin folds and craniofacial and limb deformities
      associated with TD.
    explanation: >-
      Prenatal imaging study documents redundant skin folds as part of the TD
      fetal phenotype; included here because the same series contains a
      molecularly confirmed TD2 case.
- name: Severe global developmental delay
  description: >
    Long-term survivors show severe psychomotor delay, with the highest
    developmental level in the largest cohort approximating 2 years of age.
  notes: Observed in long-term survivors only; most cases are perinatally lethal.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:34597445
    reference_title: "Development of individuals with thanatophoric dysplasia surviving beyond infancy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All individuals showed severely delayed psychomotor development. The
      highest level of psychosocial development was equivalent to that at 2
      years of age.
    explanation: >-
      Characterizes the developmental ceiling in surviving TD individuals.
- name: Severe short stature (survivors)
  description: >
    Long-term survivors show extreme growth deficiency with birth length
    averaging 36 cm and adult height below -15.2 SD.
  notes: Observed in long-term survivors only.
  phenotype_term:
    preferred_term: Short stature
    term:
      id: HP:0004322
      label: Short stature
  evidence:
  - reference: PMID:34597445
    reference_title: "Development of individuals with thanatophoric dysplasia surviving beyond infancy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The mean length at birth was 36 cm (-3.4 SD to -7.9 SD). The adult height
      (age >16 years) was <-15.2 SD.
    explanation: >-
      Quantifies the extreme growth deficiency in TD survivors.
- name: Acanthosis nigricans (survivors)
  description: >
    Acanthosis nigricans is among the skin disorders reported in long-term
    survivors.
  notes: >-
    Observed in long-term survivors. This skin finding is shared with
    SADDAN syndrome, which also has an FGFR3 K650 mutation (K650M).
  phenotype_term:
    preferred_term: Acanthosis nigricans
    term:
      id: HP:0000956
      label: Acanthosis nigricans
  evidence:
  - reference: PMID:34597445
    reference_title: "Development of individuals with thanatophoric dysplasia surviving beyond infancy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Skin disorders (acanthosis nigricans and seborrheic keratoses) were common.
    explanation: >-
      Documents acanthosis nigricans in TD long-term survivors, a finding
      shared with the related FGFR3 K650M SADDAN phenotype.
genetic:
- name: FGFR3 K650E mutation
  association: Causative
  gene_term:
    preferred_term: FGFR3
    term:
      id: hgnc:3690
      label: FGFR3
  notes: >
    The c.1948A>G (p.Lys650Glu) mutation is the specific and consistent cause of
    TD2. This mutation occurs at a CpG dinucleotide hotspot, explaining its
    recurrence. Unlike TD1, which has multiple causative mutations in the
    extracellular and transmembrane domains, TD2 is genetically homogeneous.
    The same codon is affected in SADDAN syndrome (K650M) and when acquired
    somatically, K650E contributes to bladder cancer and multiple myeloma.
  variants:
  - name: c.1948A>G (p.Lys650Glu)
    description: >-
      Substitution in the tyrosine kinase activation loop that introduces a
      glutamate residue mimicking activation-loop phosphorylation, causing
      constitutive kinase activity.
  evidence:
  - reference: PMID:7773297
    reference_title: "Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A sporadic mutation causing a Lys650Glu change in the tyrosine kinase
      domain of FGFR3 was found in 16 of 16 individuals with one type of TD.
    explanation: >-
      Original identification of the K650E mutation in all 16 TD2 cases.
  - reference: PMID:8845844
    reference_title: "Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      While TD2 was accounted for by a single recurrent mutation in the tyrosine
      kinase 2 domain, TD1 resulted from either stop codon mutations or missense
      mutations in the extracellular domain of the gene.
    explanation: >-
      Confirms TD2 genetic homogeneity with a single recurrent tyrosine
      kinase domain mutation, in contrast to TD1 heterogeneity.
  - reference: PMID:21204232
    reference_title: "Thanatophoric dysplasia type II with encephalocele and semilobar holoprosencephaly: Insights into its pathogenesis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the K650E mutation involving the change of a lysine to glutamic acid
      ("Lys650Glu") has been found in all TD2 cases to date
    explanation: >-
      Confirms 100% genotype-phenotype correlation for K650E in TD2.
animal_models:
- species: Mouse (Mus musculus)
  genotype: Fgfr3 K644E knock-in (equivalent to human K650E)
  description: >
    Heterozygous Fgfr3(TD/+) mice express the mutant allele at approximately
    20% of wild-type level and exhibit mild bone dysplasia. Homozygous
    Fgfr3(TD/TD) mice show severe retardation of bone growth resembling
    achondroplasia, with dramatically reduced proliferation of growth plate
    cartilage, macrocephaly, and shortening of long bones. The severity is
    directly linked to the expression level of the mutated Fgfr3.
  genes:
  - preferred_term: FGFR3
    term:
      id: hgnc:3690
      label: FGFR3
  associated_phenotypes:
  - Rhizomelic short stature
  - Macrocephaly
  evidence:
  - reference: PMID:9887329
    reference_title: "A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      the Lys644Glu mutation resulted in retarded endochondral bone growth with
      severity directly linked to the expression level of the mutated Fgfr3
    explanation: >-
      First knock-in mouse model of the TD2-equivalent mutation, showing
      dose-dependent bone growth retardation.
  - reference: PMID:9887329
    reference_title: "A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      when the copy number of the mutant allele increased from one (Fgfr3(TD/+)
      to two (Fgfr3(TD/TD), the retardation of bone growth became more severe
      and showed phenotypes resembling those of achondroplasia patients,
      characterized by a dramatically reduced proliferation of growth plate
      cartilage, macrocephaly and shortening of the long bones
    explanation: >-
      Homozygous mice recapitulate key skeletal features including
      macrocephaly and limb shortening.
- species: Mouse (Mus musculus)
  genotype: FGFR3(K650E) targeted expression in appendicular skeleton
  description: >
    Transgenic mice expressing FGFR3 K650E in the appendicular skeleton develop
    a block in chondrocyte differentiation at the prehypertrophic stage, with
    persistent Sox9 expression, beta-catenin downregulation, and poor
    vascularization of primary ossification centers. This model directly
    demonstrates the Sox9/beta-catenin circuit disruption mechanism.
  genes:
  - preferred_term: FGFR3
    term:
      id: hgnc:3690
      label: FGFR3
  evidence:
  - reference: PMID:22843502
    reference_title: "Disruption of a Sox9-β-catenin circuit by mutant Fgfr3 in thanatophoric dysplasia type II."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Using a mouse model of thanatophoric dysplasia type II in which
      FGFR3(K650E) expression was directed to the appendicular skeleton, we show
      that the mutant receptor caused a block in chondrocyte differentiation
      specifically at the prehypertrophic stage
    explanation: >-
      Targeted expression model directly demonstrates the differentiation
      block mechanism.
- species: Mouse (Mus musculus)
  genotype: FGFR3(K650E) in postmitotic glutamatergic neurons (Nex-Cre)
  description: >
    Transgenic mice expressing constitutively active FGFR3 K650E in postmitotic
    glutamatergic neurons develop cortical dysplasia with disrupted radial
    migration of late-born CUX1-positive neurons, reduced radial glial
    processes, and axonal tract abnormalities. This model demonstrates FGFR3
    gain-of-function effects on brain development independent of skeletal
    abnormalities.
  genes:
  - preferred_term: FGFR3
    term:
      id: hgnc:3690
      label: FGFR3
  evidence:
  - reference: PMID:33116259
    reference_title: "Enhanced FGFR3 activity in postmitotic principal neurons during brain development results in cortical dysplasia and axonal tract abnormality."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      FGFR3 GOF in postmitotic neurons not only alters axonal growth of
      postmitotic neurons but also impairs RGC neurogenesis and radial glia
      processes
    explanation: >-
      Demonstrates primary CNS effects of FGFR3 K650E beyond skeletal
      phenotypes, relevant to the developmental delay in TD2 survivors.
experimental_models:
- name: TD1 and ACH iPSC-derived chondrocytes (statin rescue)
  description: >
    Patient-specific iPSCs from thanatophoric dysplasia type I and
    achondroplasia patients were differentiated into chondrocytes, recapitulating
    degraded cartilage formation. Statin treatment corrected the degraded
    cartilage phenotype in both TD1 and ACH iPSC-derived chondrocytes,
    suggesting potential therapeutic approaches.
  experimental_model_type: IPSC_DERIVED_MODEL
  cell_types:
  - preferred_term: Chondrocyte
    term:
      id: CL:0000138
      label: chondrocyte
  cell_source: iPSC
  evidence:
  - reference: PMID:25231866
    reference_title: "Statin treatment rescues FGFR3 skeletal dysplasia phenotypes."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      The chondrogenic differentiation of TD1 iPSCs and ACH iPSCs resulted in
      the formation of degraded cartilage
    explanation: >-
      Patient-derived iPSCs recapitulate the cartilage defect, providing
      a human cellular model for FGFR3 chondrodysplasias.
  - reference: PMID:25231866
    reference_title: "Statin treatment rescues FGFR3 skeletal dysplasia phenotypes."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      statins could correct the degraded cartilage in both chondrogenically
      differentiated TD1 and ACH iPSCs
    explanation: >-
      Demonstrates statin-mediated rescue of FGFR3 chondrodysplasia
      phenotypes in patient-derived iPSC models.
- name: ATDC5 chondrogenic cells expressing TDII-FGFR3
  description: >
    ATDC5 chondrogenic cell line expressing the TDII FGFR3 K650E mutation
    demonstrates constitutive PLCgamma-STAT1 signaling leading to
    caspase-dependent apoptosis. This model established the PLCgamma-STAT1
    apoptotic signaling axis in FGFR3 chondrodysplasia.
  experimental_model_type: CELL_LINE
  cell_types:
  - preferred_term: Chondrocyte
    term:
      id: CL:0000138
      label: chondrocyte
  cell_source: immortalized
  evidence:
  - reference: PMID:17561467
    reference_title: "Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via PLCgamma-activated STAT1."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      the constitutively active forms of FGFR3 (TDII-FGFR3) and STAT1 (STAT1-C)
      induce apoptosis of chondrogenic ATDC5 cells via caspase activity.
      DN-PLCgamma reduced the apoptosis of ATDC5 cells expressing TDII-FGFR3
    explanation: >-
      Identifies PLCgamma as the mediator between FGFR3 K650E and STAT1
      activation leading to chondrocyte apoptosis.
- name: PC12 cells expressing inducible K650E FGFR3
  description: >
    PC12 cell lines (rat pheochromocytoma) stably expressing inducible FGFR3
    with the TDII K650E mutation show sustained ligand-independent ERK1/2
    activation and STAT1/3 activation. RNA interference showed that sustained
    ERK1/2 (not STAT1/3) is required for the differentiation phenotype,
    establishing the relative contributions of MAPK and STAT pathways.
  experimental_model_type: CELL_LINE
  cell_types:
  - preferred_term: Chromaffin cell (PC12)
    term:
      id: CL:0000166
      label: chromaffin cell
  cell_source: immortalized
  evidence:
  - reference: PMID:15843401
    reference_title: "Sustained ERK1/2 but not STAT1 or 3 activation is required for thanatophoric dysplasia phenotypes in PC12 cells."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      sustained ERK1/2 activity is required for this ligand-independent
      differentiation
    explanation: >-
      Establishes ERK/MAPK as the functionally required pathway for the
      K650E differentiation phenotype.
diagnosis:
- name: Prenatal Ultrasound and Radiographic Recognition
  description: >-
    TD2 is usually recognized prenatally by severe micromelia with a narrow
    thorax, straight short femora, hydrocephalus or other brain findings, and
    cloverleaf skull. Straight femora plus cloverleaf skull make the TD2 boundary
    operational against TD1, where femora are typically curved and cloverleaf
    skull is absent or less prominent.
  diagnosis_term:
    preferred_term: prenatal clinical imaging procedure
    term:
      id: MAXO:0000005
      label: clinical imaging procedure
  evidence:
  - reference: PMID:11241532
    reference_title: "Prenatal diagnosis and genetic analysis of type I and type II thanatophoric dysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The TD2 fetus was characterized by polyhydramnios, short limbs, a narrow
      thoracic cage, straight short femora, hydrocephalus and a cloverleaf skull
      at 24 weeks' gestation.
    explanation: >-
      Prenatal sonography documents the TD2 imaging pattern and the straight
      femur/cloverleaf skull distinction from TD1.
  - reference: PMID:29458880
    reference_title: "Prenatal diagnosis of hydrancephaly and enlarged cerebellum and cisterna magna in a fetus with thanatophoric dysplasia type II and a review of prenatal diagnosis of brain anomalies associated with thanatophoric dysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Fetuses with TD2 may present increased NT, early onset hydrocephalus,
      enlarged cerebellum and cisterna magna, and hydrancephaly on prenatal
      ultrasound.
    explanation: >-
      This TD2 prenatal report supports explicitly considering brain and
      posterior fossa abnormalities during diagnostic imaging.
- name: Molecular Confirmation of FGFR3 K650E
  description: >-
    Definitive TD2 diagnosis is confirmed by identifying the heterozygous FGFR3
    c.1948A>G, p.Lys650Glu (K650E) pathogenic variant. Prenatal molecular
    confirmation can be performed rapidly on uncultured amniocytes when
    ultrasound suggests TD2; broader FGFR3 sequencing or skeletal-dysplasia
    testing is appropriate when imaging is atypical.
  diagnosis_term:
    preferred_term: molecular genetic testing
    term:
      id: MAXO:0000533
      label: molecular genetic testing
  evidence:
  - reference: PMID:24075385
    reference_title: "Rapid detection of K650E mutation in FGFR3 using uncultured amniocytes in a pregnancy affected with fetal cloverleaf skull, occipital pseudoencephalocele, ventriculomegaly, straight short femurs, and thanatophoric dysplasia type II."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A molecular analysis of FGFR3 using uncultured amniocytes is useful for
      the rapid confirmation of TD2 at prenatal diagnosis.
    explanation: >-
      This directly supports uncultured-amniocyte FGFR3 testing for rapid
      prenatal TD2 confirmation.
  - reference: PMID:20301540
    reference_title: "Thanatophoric Dysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The diagnosis of TD is established in a proband with characteristic
      clinical and/or radiologic features and/or a heterozygous pathogenic
      variant in FGFR3 identified on molecular genetic testing.
    explanation: >-
      GeneReviews supports molecular confirmation of thanatophoric dysplasia
      when clinical or radiographic features are present.
- name: Genetic Counseling for De Novo Recurrence Risk
  description: >-
    Counseling should explain that TD2 is autosomal dominant but usually caused
    by a de novo FGFR3 K650E variant. Sibling recurrence risk is therefore not
    substantially above the population baseline after one affected pregnancy,
    while the theoretical possibility of parental germline mosaicism should still
    be discussed.
  diagnosis_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
  evidence:
  - reference: PMID:20301540
    reference_title: "Thanatophoric Dysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      TD is inherited in an autosomal dominant manner; the majority of probands
      have a de novo FGFR3 pathogenic variant.
    explanation: >-
      GeneReviews supports autosomal dominant inheritance with most cases caused
      by de novo FGFR3 pathogenic variants.
  - reference: PMID:20301540
    reference_title: "Thanatophoric Dysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Risk of sib recurrence for parents who have had one affected child is not
      significantly increased over that of the general population.
    explanation: >-
      GeneReviews provides the recurrence-risk counseling point requested by the
      review.
  - reference: PMID:7773297
    reference_title: "Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A sporadic mutation causing a Lys650Glu change in the tyrosine kinase
      domain of FGFR3 was found in 16 of 16 individuals with one type of TD.
    explanation: >-
      The foundational molecular series supports K650E as the recurrent sporadic
      TD2-defining variant.
treatments:
- name: Supportive and palliative care
  description: >
    Most affected infants die shortly after birth from respiratory failure.
    Palliative care is typically provided. Rare long-term survivors require
    continuous ventilatory support, and some can be transitioned to home-based
    care with meticulous respiratory and nutritional management. The long-term
    survivor literature is generally thanatophoric dysplasia-wide and not always
    subtype-resolved, so survivor management claims should not be read as
    confirmed TD2-specific unless a report documents the subtype. For survivors,
    management also includes monitoring and treatment of hydrocephalus,
    craniocervical junction constriction, seizures, hearing impairment, and
    developmental complications.
  treatment_term:
    preferred_term: Supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:34597445
    reference_title: "Development of individuals with thanatophoric dysplasia surviving beyond infancy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Long-term survival of TD individuals is common. Some individuals enjoy
      home-based lives; however, they are severely psychosocially and physically
      disabled and require meticulous respiratory and nutritional support.
    explanation: >-
      Characterizes the intensive supportive care needs of TD long-term
      survivors, while not establishing that all reported survivors are TD2.
  - reference: PMID:20301540
    reference_title: "Thanatophoric Dysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Other treatment measures may include shunt placement for hydrocephalus,
      suboccipital decompression for relief of craniocervical junction
      constriction, anti-seizure medication to control seizures, and hearing
      aids.
    explanation: >-
      GeneReviews supports the survivor-management details for neurologic,
      cranial-base, seizure, and hearing complications.
- name: Statin therapy (preclinical)
  description: >
    Statins (lovastatin, rosuvastatin) corrected degraded cartilage formation in
    TD1 and achondroplasia iPSC-derived chondrocyte models, with additional
    achondroplasia mouse rescue. This is preclinical FGFR3 chondrodysplasia
    evidence, not direct TD2 treatment evidence, and there is no clinical
    application or trial evidence for TD2 newborns.
  treatment_term:
    preferred_term: Statin therapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:25231866
    reference_title: "Statin treatment rescues FGFR3 skeletal dysplasia phenotypes."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      statins could correct the degraded cartilage in both chondrogenically
      differentiated TD1 and ACH iPSCs.
    explanation: >-
      This supports the in vitro component of the preclinical statin hypothesis,
      while showing that the patient-derived iPSC evidence is TD1/ACH rather
      than TD2.
  - reference: PMID:25231866
    reference_title: "Statin treatment rescues FGFR3 skeletal dysplasia phenotypes."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Treatment of ACH model mice with statin led to a significant recovery of
      bone growth.
    explanation: >-
      This supports additional model-organism preclinical rescue in
      achondroplasia, not clinical or TD2-specific therapy.
notes: >
  TD2 is distinguished from TD1 by straight (rather than curved) femurs and frequent
  cloverleaf skull. Both types share severe limb shortening, narrow thorax, and
  perinatal lethality. The genotype-phenotype correlation is clear: TD2 is consistently
  caused by the K650E mutation in the kinase domain activation loop, while TD1 is
  caused by various mutations in the extracellular and transmembrane domains. The
  K650E mutation is at the same codon as the K650M mutation causing SADDAN syndrome,
  but K650E causes more severe receptor activation and a more severe phenotype. The
  same K650E mutation, when acquired somatically, is also found in bladder cancer
  and multiple myeloma, indicating the broader oncogenic potential of this
  gain-of-function allele.
datasets:
references:
- reference: PMID:7773297
  title: Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3.
  findings: []
- reference: PMID:8845844
  title: Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1).
  findings: []
- reference: PMID:9887329
  title: A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors.
  findings: []
- reference: PMID:9582336
  title: Fibroblast growth factor receptor 3 mutations promote apoptosis but do not alter chondrocyte proliferation in thanatophoric dysplasia.
  findings: []
- reference: PMID:14751560
  title: Overexpression of FGFR3, Stat1, Stat5 and p21Cip1 correlates with phenotypic severity and defective chondrocyte differentiation in FGFR3-related chondrodysplasias.
  findings: []
- reference: PMID:15843401
  title: Sustained ERK1/2 but not STAT1 or 3 activation is required for thanatophoric dysplasia phenotypes in PC12 cells.
  findings: []
- reference: PMID:17561467
  title: Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via PLCgamma-activated STAT1.
  findings: []
- reference: PMID:20034074
  title: Review of the recently defined molecular mechanisms underlying thanatophoric dysplasia and their potential therapeutic implications for achondroplasia.
  findings: []
- reference: PMID:22843502
  title: Disruption of a Sox9-β-catenin circuit by mutant Fgfr3 in thanatophoric dysplasia type II.
  findings: []
- reference: PMID:23972473
  title: Structural mimicry of a-loop tyrosine phosphorylation by a pathogenic FGF receptor 3 mutation.
  findings: []
- reference: PMID:25231866
  title: Statin treatment rescues FGFR3 skeletal dysplasia phenotypes.
  findings: []
- reference: PMID:33116259
  title: Enhanced FGFR3 activity in postmitotic principal neurons during brain development results in cortical dysplasia and axonal tract abnormality.
  findings: []
- reference: PMID:34597445
  title: Development of individuals with thanatophoric dysplasia surviving beyond infancy.
  findings: []
- reference: PMID:29458880
  title: Prenatal diagnosis of hydrancephaly and enlarged cerebellum and cisterna magna in a fetus with thanatophoric dysplasia type II and a review of prenatal diagnosis of brain anomalies associated with thanatophoric dysplasia.
  findings: []
- reference: PMID:21204232
  title: Thanatophoric dysplasia type II with encephalocele and semilobar holoprosencephaly - Insights into its pathogenesis.
  findings: []
- reference: PMID:18923003
  title: FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway.
  findings: []
- reference: PMID:18698630
  title: The population-based prevalence of achondroplasia and thanatophoric dysplasia in selected regions of the US.
  findings: []
- reference: PMID:3130852
  title: Thanatophoric dysplasia and cloverleaf skull.
  findings: []
- reference: PMID:11241532
  title: Prenatal diagnosis and genetic analysis of type I and type II thanatophoric dysplasia.
  findings: []
- reference: PMID:23323754
  title: "Thanatophoric dysplasia: autopsy findings over a 25-year period."
  findings: []
- reference: PMID:24075385
  title: "Rapid detection of K650E mutation in FGFR3 using uncultured amniocytes in a pregnancy affected with fetal cloverleaf skull, occipital pseudoencephalocele, ventriculomegaly, straight short femurs, and thanatophoric dysplasia type II."
  findings: []
- reference: PMID:11965423
  title: "[Thanatophoric dysplasia: report of 2 cases with neuropathological study]."
  findings: []
- reference: PMID:33520059
  title: "Thanatophoric dysplasia: a case report."
  findings: []
- reference: PMID:20301540
  title: Thanatophoric Dysplasia.
  tags:
  - GeneReviews
  findings: []
📚

References & Deep Research

References

24
PMID:7773297
Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3.
No top-level findings curated for this source.
PMID:8845844
Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1).
No top-level findings curated for this source.
PMID:9887329
A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors.
No top-level findings curated for this source.
PMID:9582336
Fibroblast growth factor receptor 3 mutations promote apoptosis but do not alter chondrocyte proliferation in thanatophoric dysplasia.
No top-level findings curated for this source.
PMID:14751560
Overexpression of FGFR3, Stat1, Stat5 and p21Cip1 correlates with phenotypic severity and defective chondrocyte differentiation in FGFR3-related chondrodysplasias.
No top-level findings curated for this source.
PMID:15843401
Sustained ERK1/2 but not STAT1 or 3 activation is required for thanatophoric dysplasia phenotypes in PC12 cells.
No top-level findings curated for this source.
PMID:17561467
Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via PLCgamma-activated STAT1.
No top-level findings curated for this source.
PMID:20034074
Review of the recently defined molecular mechanisms underlying thanatophoric dysplasia and their potential therapeutic implications for achondroplasia.
No top-level findings curated for this source.
PMID:22843502
Disruption of a Sox9-β-catenin circuit by mutant Fgfr3 in thanatophoric dysplasia type II.
No top-level findings curated for this source.
PMID:23972473
Structural mimicry of a-loop tyrosine phosphorylation by a pathogenic FGF receptor 3 mutation.
No top-level findings curated for this source.
PMID:25231866
Statin treatment rescues FGFR3 skeletal dysplasia phenotypes.
No top-level findings curated for this source.
PMID:33116259
Enhanced FGFR3 activity in postmitotic principal neurons during brain development results in cortical dysplasia and axonal tract abnormality.
No top-level findings curated for this source.
PMID:34597445
Development of individuals with thanatophoric dysplasia surviving beyond infancy.
No top-level findings curated for this source.
PMID:29458880
Prenatal diagnosis of hydrancephaly and enlarged cerebellum and cisterna magna in a fetus with thanatophoric dysplasia type II and a review of prenatal diagnosis of brain anomalies associated with thanatophoric dysplasia.
No top-level findings curated for this source.
PMID:21204232
Thanatophoric dysplasia type II with encephalocele and semilobar holoprosencephaly - Insights into its pathogenesis.
No top-level findings curated for this source.
PMID:18923003
FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway.
No top-level findings curated for this source.
PMID:18698630
The population-based prevalence of achondroplasia and thanatophoric dysplasia in selected regions of the US.
No top-level findings curated for this source.
PMID:3130852
Thanatophoric dysplasia and cloverleaf skull.
No top-level findings curated for this source.
PMID:11241532
Prenatal diagnosis and genetic analysis of type I and type II thanatophoric dysplasia.
No top-level findings curated for this source.
PMID:23323754
Thanatophoric dysplasia: autopsy findings over a 25-year period.
No top-level findings curated for this source.
PMID:24075385
Rapid detection of K650E mutation in FGFR3 using uncultured amniocytes in a pregnancy affected with fetal cloverleaf skull, occipital pseudoencephalocele, ventriculomegaly, straight short femurs, and thanatophoric dysplasia type II.
No top-level findings curated for this source.
PMID:11965423
[Thanatophoric dysplasia: report of 2 cases with neuropathological study].
No top-level findings curated for this source.
PMID:33520059
Thanatophoric dysplasia: a case report.
No top-level findings curated for this source.
PMID:20301540
Thanatophoric Dysplasia.
No top-level findings curated for this source.

Deep Research

3
Asta ▸
Asta Literature Retrieval: Pathophysiology and clinical mechanisms of Thanatophoric Dysplasia Type 2. Core disease mechanisms, molecular and cel...
Asta Scientific Corpus Retrieval 19 citations 2026-04-02T15:45:52.196188

Asta Literature Retrieval: Pathophysiology and clinical mechanisms of Thanatophoric Dysplasia Type 2. Core disease mechanisms, molecular and cel...

This report is retrieval-only and is generated directly from Asta results.

  • Papers retrieved: 19
  • Snippets retrieved: 20

Relevant Papers

[1] EndoCompass Project: Research Roadmap for Calcium and Bone Endocrinology

  • Authors: K. Jähn-Rickert, K. Z. Tomsic, A. Anastasilakis, Jean-Philippe Bertocchio, M. L. Brandi et al.
  • Year: 2025
  • Venue: Hormone Research in Pædiatrics
  • URL: https://www.semanticscholar.org/paper/fccbdcae3a86c448632e05f9c38ad2563c14284d
  • DOI: 10.1159/000549160
  • PMID: 41296665
  • PMCID: 12698132
  • Summary: This framework identifies crucial investigation areas into metabolic bone disease pathophysiology, prevention, and treatment strategies, ultimately aimed at reducing the burden of these disorders on individuals and society.
  • Evidence snippets:
  • Snippet 1 (score: 0.435) > Skeletal dysplasias encompass a large spectrum of genetic disorders of the skeleton with abnormal bone growth, structure, or strength [85]. Individually, they are rare but, collectively, due to the large number of skeletal dysplasias (>700), they result in significant morbidity. The underlying pathology remains inadequately understood and the optimal therapy is often undefined, with precision drug treatment targeting the underlying molecular mechanism not available for most skeletal dysplasias. Gene discoveries have increased exponentially, demonstrating the value of advanced genetic tools and motivating further research into the complex pathogenesis of skeletal dysplasias. > However, further basic research is required to uncover the cellular pathology and implicated molecular pathways in various forms of skeletal dysplasia. Understanding the pathophysiology of skeletal dysplasias may also benefit a larger patient population. This is evidenced by anti-sclerostin treatment for osteoporosis [86] which, at present, is in clinical trials for osteogenesis imperfecta. Preclinical data show positive effects on bone mass and strength [87]. > The spectrum of disease manifestations of various skeletal dysplasias in different phases of life and health projections across the life course remain inadequately studied. Research on therapeutic approaches needs to focus not only on correcting the pathophysiology but also, more broadly, on surgical approaches, rehabilitation, functional/environmental adaptations, preventative measures, pain management, psychological support, and quality of life. Patient groups must be involved in identifying these research goals. International registries should be utilized to collect and analyse such data. > A multidisciplinary approach is of particular importance in genetic skeletal disorders, to enable cohesive care throughout the life course. The patients have a range of physical impairments due to their skeletal disorder, but also a disease-specific spectrum of extraskeletal manifestations requiring medical attention. These may include, for example, dental and oral health problems, immune deficiency, impaired hearing, and neurological or ophthalmologic manifestations.

[2] A Roadmap to Gene Discoveries and Novel Therapies in Monogenic Low and High Bone Mass Disorders

  • Authors: M. Formosa, D. Bergen, C. Gregson, A. Maurizi, A. Kämpe et al.
  • Year: 2021
  • Venue: Frontiers in Endocrinology
  • URL: https://www.semanticscholar.org/paper/be13ff3ea01dc5719f2c63b2cbf5d9f77bafd659
  • DOI: 10.3389/fendo.2021.709711
  • PMID: 34539568
  • PMCID: 8444146
  • Citations: 21
  • Summary: The monogenic forms of rare low and high rare bone Mass disorders known to date are described, a roadmap to unravel the genetic determinants of monogenic rare bone mass disorders is provided, using proper phenotyping and genotyping methods are provided, and different genetic validation approaches paving the way for future treatments are described.
  • Evidence snippets:
  • Snippet 1 (score: 0.430) > Skeletal development is regulated by numerous genetic factors that guide the growth, modeling and remodeling of skeletal structures starting in early fetal development and continuing throughout life. These processes are crucial for attainment of normal height, skeletal patterning, bone shape, and mobility, but also for maintenance of normal bone mass and fracture resistance. Defects in the involved genes result in a large and heterogeneous group of disorders, collectively called skeletal dysplasias, in which the primary features are confined to the skeleton. More than 460 different forms of skeletal dysplasia, most of them monogenic, have been recognized (1). They are estimated to affect approximately 1/5,000 children (2,3), and can have distinct clinical manifestations and course. Clinical outcomes range in severity from neonatal lethality to only mild growth retardation, deformity or fracture risk. Diagnosis is based on growth pattern and other clinical characteristics, skeletal imaging, bone density testing, biochemical diagnostics, and genetic tests. Although the genetic basis has been described and mutations in the responsible genes identified in a significant proportion of these conditions, for several distinct skeletal dysplasia phenotypes the genetic cause is still not known (1). > Within this large group of genetic skeletal disorders, monogenic disorders affecting bone mass comprise an expanding subgroup (1,4). This includes disorders with low bone mass and skeletal fragility, and disorders leading to increased bone mass, both commonly associated with extraskeletal complications (5,6). Due to significant variability in severity, diagnosis can be challenging. Importantly, the underlying molecular genetic mechanisms for these disorders remain inadequately explored and, in several entities, the causative genetic defect, and underlying cellular and molecular pathophysiology are still uncharacterized. > The various skeletal dysplasia delineated to date have provided important information about the molecular pathways governing skeletal health both in these conditions and in the general population, underscoring the significance of new gene discoveries not only for the individuals affected by the monogenic rare bone mass disorder, but also more widely to the musculoskeletal research field (7). Indeed, the large wealth of data generated from monogenic and polygenic bone mass disorders, frailty and other musculoskeletal traits, have led

[3] Changes in Serum Proteomic Profiles at Different Stages of Pregnancy Toxemia in Goats

  • Authors: M. Uzti̇mür, C. N. Ünal, Gurler Akpinar
  • Year: 2025
  • Venue: Journal of Veterinary Internal Medicine
  • URL: https://www.semanticscholar.org/paper/4b9c488b5dbd65d7b26fd2ad9aed70e8c4b59942
  • DOI: 10.1111/jvim.70139
  • PMID: 40492724
  • PMCID: 12150350
  • Summary: Understanding the serum proteome profiles of goats with pregnancy toxemia might help identify the proteomes and pathways responsible for the development of this disease and improve diagnosis and treatment.
  • Evidence snippets:
  • Snippet 1 (score: 0.425) > The pathophysiology and progression of this disease are not fully understood. > Traditional biomedical research has focused on the analysis of single genes, proteins, metabolites, or metabolic pathways in diseases. This molecular reductionist approach is based on the assumption that identifying genetic variations and molecular components will lead to new treatments for diseases [13][14][15][16]. However, many diseases are complex and multifactorial, and in order to determine the phenotype of such diseases, it is necessary to understand the changes that occur in more than one gene, pathway, protein, or metabolite at the cellular, tissue, and organismal levels [17][18][19]. Therefore, in recent years, proteomics, as one field of multi-omics technologies, has helped in evaluating the complex pathogenetic mechanisms of different diseases from a broad perspective and has made substantial contributions [20,21]. In veterinary medicine, proteomic analysis of metabolic diseases such as ketosis [16], hypocalcemia [22], and fatty liver [23] in dairy cows has contributed valuable insights for the definition of new pathophysiological pathways and new diagnosis and treatment protocols for these diseases. The proteomic approach can contribute importantly to a broad and detailed understanding of the changes that occur at the organismal level associated with the increase in BHBA concentration in goats with pregnancy toxemia. Our aim was to evaluate the serum protein profiles of goats with SPT or CPT using proteomic techniques to determine the proteomic profiles of these animals and to identify the relevant pathophysiological mechanisms.

[4] A Comprehensive Study of De Novo Mutations on the Protein-Protein Interaction Interfaces Provides New Insights into Developmental Delay

  • Authors: Dhruba Tara Maharjan, Weichen Song, Zhe Liu, Weidi Wang, Wenxiang Cai et al.
  • Year: 2022
  • Venue: Biomolecules
  • URL: https://www.semanticscholar.org/paper/cf81638fe2c43e5a6dc5bf24e4523f0f192068db
  • DOI: 10.3390/biom12111643
  • PMID: 36358993
  • PMCID: 9687726
  • Summary: A comprehensive study indicated the significant role of PPI interface DNMs in developmental delay pathogenicity and identified 302 DD-related PsychiPPIs, defined as PPIs harboring a statistically significant number of DNM missenses at their interface, and 42 DD candidate genes from Psychi PPI.
  • Evidence snippets:
  • Snippet 1 (score: 0.424) > Several FGFR3 de novo mutations were identified in thanatophoric dysplasia (TD) patients.Some patients with these mutations have an intellectual disability and severe skeletal deformities, which correspond to the symptom of DD [95].Additionally, research has shown that ALOX5 is related to memory deficits and synaptic dysfunction in a mouse model of Alzheimer's disease [96].Despite the supportive evidence, our hypothesis is not entirely settled.Studies involved in cell or animal models are required to prove our findings. > This study showed a significant association between PPI interface DNMs and developmental delay, combined with our PsychiPPI-based disease-related genes searching framework.With the development of whole exome sequencing, researchers worldwide could identify thousands of DNM missenses in a large-scale study within a relevantly short time.We may contribute to discovering disease mechanisms and early diagnosis of developmental delay and other potential neuropsychiatric diseases.

[5] A Case of Thanatophoric Dysplasia Type 2: A Novel Mutation

  • Authors: Selvi Gülaşı, A. Atıcı, Y. Celik
  • Year: 2015
  • Venue: Journal of Clinical Research in Pediatric Endocrinology
  • URL: https://www.semanticscholar.org/paper/bb860b6353d6bdcb68c39ce5405e7bcf0053a21c
  • DOI: 10.4274/jcrpe.1703
  • PMID: 25800480
  • PMCID: 4439897
  • Citations: 4
  • Summary: A male patient who showed clinical findings congruent with TD type 2 and a new mutation in the FGFR3 gene, a finding which has not been reported previously, is reported.
  • Evidence snippets:
  • Snippet 1 (score: 0.423) > A Case of Thanatophoric Dysplasia Type 2: A Novel Mutation

[6] Mitochondrial Dysfunction in Diabetes: Shedding Light on a Widespread Oversight

  • Authors: F. Iheagwam, A. J. Joseph, E. D. Adedoyin, Olawumi Toyin Iheagwam, Samuel Akpoyowvare Ejoh
  • Year: 2025
  • Venue: Pathophysiology
  • URL: https://www.semanticscholar.org/paper/dbf8042761c1a5fc50f8cd894cc498505abac7cb
  • DOI: 10.3390/pathophysiology32010009
  • PMID: 39982365
  • PMCID: 12077258
  • Citations: 23
  • Summary: This review aims to elucidate the complex link between mitochondrial dysfunction and diabetes, covering the spectrum of diabetes types, the role of mitochondria in insulin resistance, highlighting pathophysiological mechanisms, mitochondrial DNA damage, and altered mitochondrial biogenesis and dynamics.
  • Evidence snippets:
  • Snippet 1 (score: 0.422) > The landscape of DM research is continuously evolving, with emerging technologies and approaches offering new insights into the pathophysiology of the disease and potential therapeutic targets. Advancements in omics technologies, encompassing genomes, transcriptomics, proteomics, and metabolomics, have transformed the molecular mechanisms underlying DM [134]. High-throughput sequencing techniques enable comprehensive analysis of genetic variants, gene expression profiles, protein abundance, and metabolite levels associated with DM and its complications [135]. Single-cell omics approaches provide unprecedented resolution and granularity, allowing researchers to dissect cellular heterogeneity and identify novel cell types, subpopulations, and signalling pathways involved in DM pathogenesis. Integrating multi-omics data sets offers a systems-level perspective of DM, unravelling complex networks of molecular interactions and regulatory circuits underlying disease progression [136]. > In addition to omics technologies, advances in imaging modalities, such as MRI, PET, and optical imaging, enable non-invasive visualisation and quantification of metabolic, functional, and structural changes. Molecular imaging probes targeting specific biomarkers and metabolic pathways provide valuable insights into disease mechanisms and treatment responses in preclinical and clinical settings [85]. Despite significant progress in DM research, numerous unanswered questions and knowledge gaps persist, hindering the ability to develop effective prevention and treatment strategies. Key areas requiring further investigation include the role of epigenetics, environmental factors, and the microbiome in DM susceptibility and progression. Moreover, the interaction between environmental cues and genetic predisposition remains incompletely understood, highlighting the need for comprehensive multi-omics studies and large-scale epidemiological analyses to identify gene-environment interactions and modifiable risk factors for DM [137]. Furthermore, the heterogeneity of DM phenotypes and clinical outcomes poses a challenge for personalised medicine approaches, necessitating robust biomarkers and predictive models to stratify patients based on disease subtypes, prognosis, and treatment response [138].

[7] New therapeutic targets in rare genetic skeletal diseases

  • Authors: M. Briggs, Peter A. Bell, M. Wright, K. A. Pirog
  • Year: 2015
  • Venue: Expert Opinion on Orphan Drugs
  • URL: https://www.semanticscholar.org/paper/1363107f71ae6d2d60abca471cddf3da5d13644b
  • DOI: 10.1517/21678707.2015.1083853
  • PMID: 26635999
  • PMCID: 4643203
  • Citations: 37
  • Influential citations: 1
  • Summary: An overview of disease mechanisms that are shared amongst groups of different GSDs and potential therapeutic approaches that are under investigation are described to generate critical mass for the identification and validation of novel therapeutic targets and biomarkers.
  • Evidence snippets:
  • Snippet 1 (score: 0.412) > proteins of the cartilage ECM such as type II collagen [50]. However, emerging knowledge suggests that the primary genetic defect may be less important than the cells' response to the expression of the mutant gene product [107]. Moreover, the largely overlooked response of a cell (i.e. chondrocyte) to the abnormal extracellular environment is also important for disease progression as illustrated by several GSDs discussed in this review. > It is important that 'omics'-based approaches and technologies are systematically applied to the study of rare GSDs so that definitive reference profiles and disease signatures are generated for each phenotype. These can then be used in a Systems Biology approach to identify both common and dissimilar pathological signatures and disease mechanisms. This approach is entirely dependent upon relevant in vitro and in vivo models (and also novel 'disease-mechanism phenocopies' [107]) for testing new diagnostic and prognostic tools and for determining the molecular mechanisms that underpin the pathophysiology so that effective therapeutic treatments can be developed and validated. This approach will eventually lead to personalized treatments and care strategies centred on shared disease mechanisms with the use of relevant biomarkers to monitor the efficacy of treatment and disease progression. > It is vital that all relevant stakeholders are involved from the outset in defining the appropriate outcomes of any potential therapeutic regime. The perceptions of a successful therapy can differ widely between the clinical academic community and the relevant patient-support groups and it is vital that there is engagement on all these issues. > In summary, the identification of causative genes and mutations for GSDs over the last 20 years, coupled with the generation and in-depth analysis of a plethora of relevant cell and mouse models, has derived new knowledge on disease mechanisms and suggested potential therapeutic targets. The fast-evolving hypothesis that clinically disparate diseases can share common disease mechanisms is a powerful concept that will generate critical mass for the identification and validation of novel therapeutic targets and biomarkers.
  • Snippet 2 (score: 0.390) > The extensive clinical variability and genetic heterogeneity of GSDs, coupled with complex disease mechanisms, renders this extensive group of rare diseases a bench to bedside challenge. Indeed, this large number of different and highly complex phenotypes makes the identification, validation and development of potential therapies almost impossible for anything other than the most common GSDs. As an alternative approach, we might consider identifying genotype-and/or phenotype-independent 'core disease mechanisms' that are shared amongst families of clinically unrelated GSDs. This approach would allow the focusing of resources into several areas of concerted investigation that have the potential to identify and validate therapeutic targets with a broad application to GSDs, inherited connective tissues as a whole and rare genetic disease in general. Indeed, Jürgen Spranger first suggested the idea of 'bone dysplasia families' in 1985 [124] and proposed that phenotypes with a similar clinical and radiographic phenotype would likely have a similar disease mechanism. Thirty years later, we can now expand upon this pioneering concept and propose that common disease mechanisms can also be shared amongst clinically different phenotypes ('common amongst the rare'). > In this context, ER stress has been associated with a diverse range of genetic diseases and chronic conditions such as skeletal dysplasia (as discussed in this review), myopathy [125], cerebro-vascular [42], kidney [126], ischaemia and cardiovascular diseases [127]. Moreover, ER stress is emerging as a very attractive target that is being successfully exploited in a broad range of diseases including neuropathy, juvenile-onset openangle glaucoma, obesity, diabetes, asthma and epidermolysis bullosa, to name but a few. Historically many GSDs were considered diseases of the ECM and proposed therapeutic interventions involved the removal and/or correction of the relevant mutated gene or abnormal gene product. This was particularly the case with dominant-negative mutations in the large structural proteins of the cartilage ECM such as type II collagen [50]. However, emerging knowledge suggests that the primary genetic defect may be less important than the cells' response to the expression of the mutant gene product [107]. Moreover, the largely overlooked response of a cell (i.e.

[8] High Fidelity of Mouse Models Mimicking Human Genetic Skeletal Disorders

  • Authors: R. Brommage, C. Ohlsson
  • Year: 2020
  • Venue: Frontiers in Endocrinology
  • URL: https://www.semanticscholar.org/paper/3b9e1d0da086028d9f89e99a06b7222353ab6b2d
  • DOI: 10.3389/fendo.2019.00934
  • PMID: 32117046
  • PMCID: 7010808
  • Citations: 25
  • Influential citations: 1
  • Summary: Data is organized for 441 human genetic bone disorders with regard to heredity, gene function, molecular pathways, and fidelity of relevant mouse models to mimic the human skeletal disorders to identify mutant genes responsible for human rare genetic skeletal disorders.
  • Evidence snippets:
  • Snippet 1 (score: 0.407) > Rare human genetic diseases cumulatively affect about 1 in 200 individuals and involve an estimated 7,000 genes. Major research efforts are underway to identify these mutant genes and characterize their disease phenotypes. Knowledge gained can guide therapies and provide hypotheses to develop future treatments. As recently summarized (1), "Genome sequencing has revolutionized the diagnosis of genetic diseases. Close collaborations between basic scientists and clinical genomicists are now needed to link genetic variants with disease causation. To facilitate such collaborations, we recommend prioritizing clinically relevant genes for functional studies, developing reference variant-phenotype databases, adopting phenotype description standards, and promoting data sharing." > Rare human genetic skeletal dysplasias affect about 1 in 5,000 individuals (2) and account for 5% of all birth defects (3). The International Skeletal Dysplasia Society (ISDS, https://www.isds. ch), promotes scientific progress in the field of skeletal dysplasias and dysostoses, meets every second year, and published skeletal nosology summaries during 2001 (4), 2006 (5), 2010 (6), 2015 (7), and 2019 (8). There are presently 441 skeletal nosology genes, with an average of 20 new genes identified yearly (Figure 1). The classification aims to (i) identify metabolic pathways active in cartilage and bone, and their regulatory mechanisms; (ii) identify cellular signaling networks and gene expression sequences implicated in skeletal development; (iii) identify candidate genes for genetic disorders; (iv) facilitate integration of data coming from spontaneous and genetically engineered mouse mutants; (v) help in developing diagnostic strategies; (vi) stimulate the design and exploration of new therapeutic possibilities; and (vii) provide a knowledge framework accessible to physicians as well as to basic scientists and thus to facilitate communication between clinical genetics and pediatrics and the basic sciences (4). > The objectives of the present review include further characterizations of these 441 skeletal nosology genes and evaluating the reliability of mutant mouse models to mimic these human skeletal disorders.

[9] Investigating the role of NPR1 in dilated cardiomyopathy and its potential as a therapeutic target for glucocorticoid therapy

  • Authors: Yaomeng Huang, Tongxin Li, Shichao Gao, Shuyu Li, Xiaoran Zhu et al.
  • Year: 2023
  • Venue: Frontiers in Pharmacology
  • URL: https://www.semanticscholar.org/paper/be229f6f2059faab4c97ec0a04bd055adab9dfe1
  • DOI: 10.3389/fphar.2023.1290253
  • PMID: 38026943
  • PMCID: 10662320
  • Citations: 3
  • Summary: Natriuretic peptide receptor 1 (NPR1) was identified as a core gene associated with DCM through bioinformatics analysis and led to substantial improvements in cardiac and renal function, accompanied by an upregulation of NPR1 expression.
  • Evidence snippets:
  • Snippet 1 (score: 0.403) > Multiple pathways and molecules are involved in this process; however, the detailed underlying mechanisms remain unclear. In recent years, with the development of high-throughput sequencing and gene chip technologies, the use of bioinformatics technology to explore the occurrence, development, and prognosis of diseases has become a hot topic for scholars worldwide (Hwang et al., 2018;Nayor et al., 2019;Rinschen et al., 2019;Sturm et al., 2019;Montaner et al., 2020). > The present study aimed to use bioinformatics technology to screen for DCM-related genes and investigate their mechanisms, with the purpose of revealing the pathogenesis of DCM and seeking treatment methods. The GSE3586 dataset, containing expression profiles related to DCM, was selected from the Gene Expression Omnibus (GEO) database. This study aimed to predict the core genes that may play crucial roles in disease progression at the molecular level through the enrichment of relevant molecular pathways associated with DCM. Furthermore, the phenotype of the core genes was validated to further support the results of the bioinformatics analysis through basic and clinical experiments. Additionally, the role of glucocorticoids in DCM treatment is discussed in this article with the purpose of providing a theoretical and experimental basis for exploring the pathogenesis of DCM and elucidating therapeutic methods. This study also provides a theoretical reference for the interpretation, early diagnosis, and treatment of DCM.

[10] Nasopharyngeal Carcinoma Signaling Pathway: An Update on Molecular Biomarkers

  • Authors: W. Tulalamba, T. Janvilisri
  • Year: 2012
  • Venue: International Journal of Cell Biology
  • URL: https://www.semanticscholar.org/paper/307cb9186444d9dad6e2e3b53763be0de76de186
  • DOI: 10.1155/2012/594681
  • PMID: 22500174
  • PMCID: 3303613
  • Citations: 93
  • Influential citations: 5
  • Summary: The molecular signaling pathways in the NPC are discussed for the holistic view of NPC development and progression and the important insights toward NPC pathogenesis may offer strategies for identification of novel biomarkers for diagnosis and prognosis.
  • Evidence snippets:
  • Snippet 1 (score: 0.398) > In the pregenomic eras, highly integrated and complex circuitry of molecular signaling in NPC pathogenesis was only partially understood. Over the past decade, the knowledge of the molecular mechanisms in NPC carcinogenesis has been rapidly accumulated. Dysregulation and abnormal protein expression of molecules in certain signaling pathways involved in cellular functions including proliferation, adhesion, survival, and apoptosis has been demonstrated in the NPC cells. Detailed information on the complex network in signaling pathway leading to a coordinated pattern of gene expression and regulation in NPC will undoubtedly provide important clues to develop novel prognostic and therapeutic strategies for this cancer. Refining molecular markers into clinically relevant assays may assist in the detection of NPC in asymptomatic patients, as well as stage classification and monitoring disease progression and treatments. Furthermore, selective regulation of particular proteins targeting cancer cell proliferation, invasion, and apoptosis is a hopeful prospect for future anticancer therapy that slow disease progression and improve survival.

[11] Signaling Pathways in Bone Development and Their Related Skeletal Dysplasia

  • Authors: Alessandra Guasto, V. Cormier-Daire
  • Year: 2021
  • Venue: International Journal of Molecular Sciences
  • URL: https://www.semanticscholar.org/paper/c5466b45e1a7e5aa8e7ad05c7d9287a9e84e9262
  • DOI: 10.3390/ijms22094321
  • PMID: 33919228
  • PMCID: 8122623
  • Citations: 51
  • Summary: The principal signaling pathways involved in bone development and their associated skeletal dysplasia are reviewed and genotype–phenotype correlations have helped to elucidate their role in skeletogenesis.
  • Evidence snippets:
  • Snippet 1 (score: 0.395) > In this review, we discussed the main signaling pathways involved in bone development and how mutations in their components have been associated with SD. It is important to highlight that even if the signaling pathways have been discussed independently, there is a complex cross-talk among them at multiple levels. This, in association with the evidence that the mutation consequences depend on the specificity of the mutations and on their temporal and spatial mode of action, makes more difficult the understanding of the physiopathological mechanisms of these diseases. Moreover, these signaling pathways can be secondarily affected by alterations in other cellular processes, such as extracellular matrix regulation or metabolic processing. Indeed, several skeletal dysplasia, that we decided to omit in this review, have been associated with mutations in these processes. Fortunately, in the last decade, the development of new technologies, like whole exome and genome sequencing has accelerated the identification of skeletal dysplasia-causing mutations. On the other hand, the development of CRISPR-Cas9 technology and of several mouse models is helping the deciphering of the physiopathological mechanisms. Advanced genetic testing is also helping the diagnosis of skeletal dysplasia. The diagnosis and management of these pathologies have long been based on clinical feature and skeletal imaging. Today, these key techniques are increasingly combined with the genetic testing in order to obtain a more accurate and early diagnosis of SD. It also aids in prognosis and in counselling families regarding genetic recurrence risk and preconceptional reproductive planning [212][213][214]. These continuous discoveries will help to expand the genotype-phenotype correlation of SD and to develop new therapeutic strategies. Nowadays, few treatments are available for SD, but several clinical trials are ongoing to validate new drugs targeting specifically these pathways in achondroplasia or FOP for example, and highlighting the importance of multidisciplinary cross talks (from bed to bench side) [215].

[12] Human Dermal Fibroblast: A Promising Cellular Model to Study Biological Mechanisms of Major Depression and Antidepressant Drug Response

  • Authors: P. Mesdom, R. Colle, É. Lebigot, S. Trabado, Eric Deflesselle et al.
  • Year: 2020
  • Venue: Current Neuropharmacology
  • URL: https://www.semanticscholar.org/paper/79368e365458486de96794333613c12a6063bf54
  • DOI: 10.2174/1570159X17666191021141057
  • PMID: 31631822
  • PMCID: 7327943
  • Citations: 12
  • Summary: This review highlights the great and still underused potential of HDF, which stands out as a very promising tool in the understanding of MDD and AD mechanisms of action.
  • Evidence snippets:
  • Snippet 1 (score: 0.393) > Background: Human dermal fibroblasts (HDF) can be used as a cellular model relatively easily and without genetic engineering. Therefore, HDF represent an interesting tool to study several human diseases including psychiatric disorders. Despite major depressive disorder (MDD) being the second cause of disability in the world, the efficacy of antidepressant drug (AD) treatment is not sufficient and the underlying mechanisms of MDD and the mechanisms of action of AD are poorly understood. Objective The aim of this review is to highlight the potential of HDF in the study of cellular mechanisms involved in MDD pathophysiology and in the action of AD response. Methods The first part is a systematic review following PRISMA guidelines on the use of HDF in MDD research. The second part reports the mechanisms and molecules both present in HDF and relevant regarding MDD pathophysiology and AD mechanisms of action. Results HDFs from MDD patients have been investigated in a relatively small number of works and most of them focused on the adrenergic pathway and metabolism-related gene expression as compared to HDF from healthy controls. The second part listed an important number of papers demonstrating the presence of many molecular processes in HDF, involved in MDD and AD mechanisms of action. Conclusion The imbalance in the number of papers between the two parts highlights the great and still underused potential of HDF, which stands out as a very promising tool in our understanding of MDD and AD mechanisms of action

[13] WNT Signaling and Bone: Lessons From Skeletal Dysplasias and Disorders

  • Authors: Yentl Huybrechts, G. Mortier, E. Boudin, W. Van Hul
  • Year: 2020
  • Venue: Frontiers in Endocrinology
  • URL: https://www.semanticscholar.org/paper/00fd0aa090f258a34c6590bc3dee4b211ecb0929
  • DOI: 10.3389/fendo.2020.00165
  • PMID: 32328030
  • PMCID: 7160326
  • Citations: 95
  • Summary: This review discusses the skeletal disorders that are included in the latest nosology of skeletal disorders and that are caused by genetic defects involving the Wingless and int-1 (WNT) signaling pathway.
  • Evidence snippets:
  • Snippet 1 (score: 0.389) > The identification of novel disease-causing genes for rare skeletal dysplasias accelerated significantly in the last decades, initially by positional cloning efforts and more recently by the availability of next-generation sequencing technology. This resulted in the identification of the disease-causing gene for 92% of the skeletal disorders (6). The increased knowledge on monogenic diseases resulted in a better understanding of the pathological mechanisms and highlighted which pathways regulate specific cellular processes. This information is also relevant for understanding more common multifactorial diseases. Furthermore, it has been shown that therapeutic targets which are based on genetic evidence from Mendelian traits as well as genome-wide association studies (GWASs) are more likely to be successful in clinical studies for multifactorial diseases (150). Here, we focused on skeletal dysplasias caused by mutations in genes that encode proteins that are directly involved in one of the WNT signaling pathways. As shown in Table 1, mutations in these genes can result in a variety of skeletal dysplasias, each with specific clinical features. The broad spectrum of clinical observations reflect the cellular and spatial functions of WNT signaling, some of them associated with embryonal development, others with bone mass and homeostasis in adult life. For example, the clinical features of RS and OMOD are similar which led to the hypothesis that all causative genes are involved in the WNT/PCP pathway which is previously shown to be important during limb development (Figure 2) (102). On the other hand, the influence of canonical WNT signaling on bone mass was highlighted by unraveling the underlying pathogenic mechanisms of disorders with a progressively increasing bone mass such as sclerosteosis, Van Buchem disease, and high bone mass phenotypes (osteosclerosis) (51,53,57,107,113). The genes causing these disorders, SOST, LRP4, LRP5, and LRP6, are all involved in the canonical WNT signaling pathway (Figure 3), and all mutations reported result in an increased canonical WNT signaling (Table 1).

[14] Role of Transcriptomics in Precision Oncology

  • Authors: Ruby Srivastava
  • Year: 2024
  • Venue: Reports of Radiotherapy and Oncology
  • URL: https://www.semanticscholar.org/paper/0bd862558bbb7286336111d9dfd232b5f905d3d9
  • DOI: 10.5812/rro-142195
  • Citations: 4
  • Summary: : Transcriptome profiling is one of the most widely used approaches in the field of multiomics research. It plays a crucial role in the prognostic, diagnostic, and predictive treatment of cancer patients. Novel next-generation sequencing (NGS) technologies permit the identification of cancer biomarkers, gene signatures, and their abnormal expression, affecting oncogenic and molecular targets and novel biomarkers for cancer therapies. Multiomics studies have changed the overall understanding o...
  • Evidence snippets:
  • Snippet 1 (score: 0.388) > : Transcriptome profiling is one of the most widely used approaches in the field of multiomics research. It plays a crucial role in the prognostic, diagnostic, and predictive treatment of cancer patients. Novel next-generation sequencing (NGS) technologies permit the identification of cancer biomarkers, gene signatures, and their abnormal expression, affecting oncogenic and molecular targets and novel biomarkers for cancer therapies. Multiomics studies have changed the overall understanding of cancer and opened a precise perspective for tumor diagnostics and therapy. The use of these approaches has strengthened our understanding of disease pathophysiology and classifications at the molecular level, including specific interference with drug mechanisms of action. Still, it has limited added value in the clinical setting. The omics data on precision medicine include the application of data from genes, transcripts, and proteins for diagnosis, monitoring of diseases, risk factor determination, counseling, and development of novel therapeutics. Bioinformatics applications have expanded statistics-based analysis toward deriving molecular pathways and process models for characterizing phenotypes and drug action mechanisms. In this review, we will discuss transcriptomics and interference analysis that allows the identification of predictive biomarkers at the molecular level to test drug response and analyze the molecular process interface of disease progression-relevant pathophysiology and mechanism of action to propose predictive biomarkers.

[15] Modelling Mitochondrial Disease in Human Pluripotent Stem Cells: What Have We Learned?

  • Authors: Cameron L. McKnight, Y. C. Low, D. Elliott, D. Thorburn, Ann E. Frazier
  • Year: 2021
  • Venue: International Journal of Molecular Sciences
  • URL: https://www.semanticscholar.org/paper/bf41f9d980522896fcd2284bd630fbb418e55941
  • DOI: 10.3390/ijms22147730
  • PMID: 34299348
  • PMCID: 8306397
  • Citations: 20
  • Summary: Mitochondrial diseases disrupt cellular energy production and are among the most complex group of inherited genetic disorders. Affecting approximately 1 in 5000 live births, they are both clinically and genetically heterogeneous, and can be highly tissue specific, but most often affect cell types with high energy demands in the brain, heart, and kidneys. There are currently no clinically validated treatment options available, despite several agents showing therapeutic promise. However, modell...
  • Evidence snippets:
  • Snippet 1 (score: 0.387) > Mitochondrial disease hPSC models provide a system to study disease gene-or mutation-related pathomechanisms in tissues relevant to the clinical phenotype. Ultimately, the long-term goal of these models would be to identify a phenotype in a clinically relevant cell type that could be used to validate efficacy of targeted treatments, or for use in highthroughput treatment trials [94][95][96] (Figure 2). > There are now a wide range of endpoints that have been validated in terminally differentiated cell types to investigate the underlying cellular mechanisms of disease and efficiently identify targetable pathways. Many of these approaches can also be adapted to suit different cell types and even organoids at scale. The tissue specific nature of mitochondrial diseases means that mitochondrial function post-differentiation can be distinct to that from the undifferentiated stem cells or original fibroblast line, often greatly exaggerating any underlying defects [97]. Additionally, detailed transcriptomic and proteomic analyses can elucidate cellular compensation mechanisms and potential target pathways to inform downstream treatment studies [98,99]. Other approaches include microscopic visualization of key cellular features to determine a mutation's impact on cell structure or function [100]. For cardiomyocytes and neurons, electrophysiology can provide highly sensitive data to identify even subtle functional changes [101]. Calcium imaging can be particularly informative in the context of mitochondrial diseases, since calcium handling is a key role of mitochondria [102,103].

[16] Type II Thanatophoric Dysplasia

  • Authors: T. Zahouani, A. Recinos, A. Gonzales, S. Kandi, B. Rajegowda
  • Year: 2016
  • Venue: Pediatrics & Therapeutics
  • URL: https://www.semanticscholar.org/paper/a94dec8eed0aa8c161cda952efef350e66982636
  • DOI: 10.4172/2161-0665.1000I120
  • Citations: 1
  • Summary: A baby girl was born at 32 weeks of gestation via vaginal delivery to a 28 y/o mother whose prenatal course was remarkable for ultrasound findings at 23 weeks suggestive of severe polyhydramnios and type II Thanatophoric Dysplasia and small compressed chest with severe pulmonary hypoplasia.
  • Evidence snippets:
  • Snippet 1 (score: 0.387) > Type II Thanatophoric Dysplasia

[17] Multi‐gene panel sequencing in highly consanguineous families and patients with congenital forms of skeletal dysplasias

  • Authors: Naseebullah Kakar, F. Rehman, Ramandeep Kaur, G. Bhavani, M. Goyal et al.
  • Year: 2024
  • Venue: Clinical Genetics
  • URL: https://www.semanticscholar.org/paper/08f6a00a89b10f2208d3e03fb37a980a49142dfc
  • DOI: 10.1111/cge.14509
  • PMID: 38378010
  • Citations: 2
  • Summary: Panel sequencing proved to be a highly effective way to decipher the genetic basis of SKDs in highly consanguineous families as well as sporadic and or familial cases from South Asia, and expand the allelic spectrum of skeletal dysplasias.
  • Evidence snippets:
  • Snippet 1 (score: 0.386) > Inherited skeletal dysplasias (SKDs) are a heterogeneous group of developmental disorders of the skeleton, also known as osteochondrodysplasias, characterized by abnormal growth of bone and cartilage.The abnormal shape and size of the skeleton lead to disproportional long bones which can result in different types of SKDs. 1 Based on radiographic and molecular features SKDs are classified into distinct groups, including proportionate and disproportionate short stature, increased bone fragility, and skeletal deformities.SKDs show remarkable clinical and genetic heterogeneity that comprises more than 750 types. 2 Each type of SKD is rare, with the overall birth incidence rate worldwide estimated to be $1 of 3300 live births. 3Relatively common SKDs include osteogenesis imperfecta (OI) also known as brittle bone disease, osteopetrosis, achondroplasia, hypochondroplasia, campomelic dysplasia, and thanatophoric dysplasia. 4inically, SKDs can present with short stature, rhizomelic or mesomelic or acromelic limb shortening, bony deformities, or spine involvement.Genetic studies of inherited SKDs offer the opportunity to identify corresponding disease genes, thus providing significant clues in understanding the pathophysiology of these disorders. 5,6This can possibly contribute to the medical and surgical treatment options of the individuals affected with SKD in order to improve their quality of life and lifespan, as exemplified in the case of some genetic types of OI. > Over the past decade, next-generation sequencing (NGS) has enhanced the identification of variants in genes associated with rare diseases, including inherited skeletal dysplasia. 5,7,8Until recently the diagnosis of SKDs usually depended on the opinions of experienced clinicians or radiologists.However, multigene panel sequencing approaches now enable the identification of the underlying genetic cause of SKDs when pathogenic variants are identified, irrespective of the clinical diagnosis.

[18] Developmental Genes and Malformations in the Hypothalamus

  • Authors: C. Díaz, L. Puelles
  • Year: 2020
  • Venue: Frontiers in Neuroanatomy
  • URL: https://www.semanticscholar.org/paper/b2148f35930e6690b57b92bb8daf3f3615a2095e
  • DOI: 10.3389/fnana.2020.607111
  • PMID: 33324176
  • PMCID: 7726113
  • Citations: 30
  • Influential citations: 2
  • Summary: The complex molecular genoarchitecture of the hypothalamus resulting from the activity of previous morphogenetic signaling centers is analyzed and some malformations related to alterations in genes implicated in the development ofThe hypothalamus are analyzed.
  • Evidence snippets:
  • Snippet 1 (score: 0.386) > Several recent monographs present structural and functional vertebrate neuroanatomy, including that of the human brain, based on the prosomeric model (Watson et al., 2010;Striedter, 2016;ten Donkelaar, 2018ten Donkelaar, , 2020;;Schröder et al., 2020;Striedter and Northcutt, 2020). The advantage of the prosomeric model compared to older models is that it is causally oriented and greatly aids the experimental assessment of molecular and genetic causal mechanisms involved in normal or pathologic neural development. It accordingly promises to aid significantly advances in system physiology and clinical physiopathology in the molecular era, though progress in this direction is still preliminary because physiologists and clinicians are still little aware of the mentioned paradigm shift. > Studies in animal models are essential to evaluate mutations in regulatory genes implicated in hypothalamic development potentially related to rare endocrine disorders associated with congenital malformations such as holoprosencephaly, septo-optic-dysplasia, and congenital obesity. Experimental animal studies, together with data of human patients and their families, are allowing the identification of relevant genes implicated in hypothalamic development, to assess the risk and progression of these rare diseases, and to evaluate possible treatments (e.g., new drugs or gene therapy). Diagnosis and treatment are two of the main problems of patients affected by rare diseases whose origin, in a high percentage (estimated up 72%), is due to the unidentified alteration of one or more genes, most of the patients being children (Nguengang Wakap et al., 2020). Genetic and clinical heterogeneity increases the intricacy of rare diseases or disorders. > For instance, holoprosencephaly (cyclopy), a brain malformation with high clinical variability, is not completely deciphered yet, though we know a number of the genes and a variety of mechanisms involved.

[19] 5. Hereditary Kidney Disorders

  • Authors: A. Stavljenic-Rukavina
  • Year: 2009
  • Venue: EJIFCC
  • URL: https://www.semanticscholar.org/paper/3130ef69f6556fdfdd741e3495c85439e6146976
  • PMID: 27683325
  • PMCID: 4975268
  • Citations: 4
  • Summary: The global increasing number of patients with ESRD urges the identification of molecular pathways involved in renal pathophysiology in order to serve as targets for either prevention or intervention.
  • Evidence snippets:
  • Snippet 1 (score: 0.384) > Hereditary kidney disorders represent significant risk for the development of end stage renal desease (ESRD). Most of them are recognized in childhood, or prenataly particularly those phenotypicaly expressed as anomalies on ultrasound examination (US) during pregnancy. They represent almost 50% of all fetal malformations detected by US (1). Furthermore many of urinary tract malformations are associated with renal dysplasia which leeds to renal failure. > Recent advances in molecular genetics have made a great impact on better understanding of underlying molecular mechanisms in different kidney and urinary tract disorders found in childhood or adults. Even some of clinical syndromes were not recognized earlier as genetic one. In monogenic kidney diseases gene mutations have been identified for Alport syndrome and thin basement membrane disease, autosomal dominant polycystic kidney disease, and tubular transporter disorders. There is evident progress in studies of polygenic renal disorders as glomerulopathies and diabetic nephropathy. The expanded knowledge on renal physiology and pathophysiology by analyzing the phenotypes caused by defected genes might gain to earlier diagnosis and provide new diagnostic and prognostic tool. The global increasing number of patients with ESRD urges the identification of molecular pathways involved in renal pathophysiology in order to serve as targets for either prevention or intervention. Molecular genetics nowadays possess significant tools that can be used to identify genes involved in renal disease including gene expression arrays, linkage analysis and association studies.

Notes

  • This provider combines search_papers_by_relevance with snippet_search.
  • No synthesis or second-stage model call is performed.
Disorder ▸

Disorder

  • Name: Thanatophoric Dysplasia Type 2
  • Category: Mendelian
  • Existing deep-research providers: falcon
  • Existing evidence reference count in YAML: 7

Key Pathophysiology Nodes

  • Severe FGFR3 gain-of-function (K650E)
  • Premature craniosynostosis
  • Deep research literature mapping

Citation Inventory (for evidence mapping)

  • DOI:10.1038/s41598-020-75537-0
  • DOI:10.1093/hmg/ddn339
  • DOI:10.1101/2022.04.11.487861
  • DOI:10.1186/s12920-023-01697-3
  • DOI:10.2741/1671
  • DOI:10.3389/fgene.2023.1032346
  • DOI:10.5005/jp-journals-10009-2023
Falcon ▸
Disease Pathophysiology Research Report
Edison Scientific Literature 22 citations 2026-04-02T15:45:48.757962

Disease Pathophysiology Research Report

Target Disease

  • Disease Name: Thanatophoric Dysplasia Type 2 (TD2)
  • MONDO ID: Not available in the provided context
  • Category: Mendelian

Executive Summary

Thanatophoric dysplasia type 2 is a perinatal‑lethal chondrodysplasia caused by a recurrent activating mutation in FGFR3, p.Lys650Glu (K650E), which produces constitutive, ligand‑independent signaling in growth‑plate chondrocytes. This hyperactivation represses chondrocyte proliferation via STAT1/p21 and impedes hypertrophic differentiation through MAPK signaling, collapsing normal endochondral ossification. FGFR3 activation also promotes premature closure of cranial base synchondroses through MAPK‑dependent BMP shifts, contributing to foramen magnum stenosis. Beyond the skeleton, FGFR3 K650E in developing neurons disrupts cortical migration and axon guidance, underlying the temporal/cortical dysplasia reported in TD. Prenatally, a markedly narrow thorax and severe limb shortening foretell respiratory failure and high perinatal lethality. Recent 2023 prenatal genomics studies underscore the high contribution of FGFR3 among fetuses with short long bones and refine severity‑linked diagnostic yield, informing counseling and management. (chen2005rolesoffgf pages 3-4, chen2005rolesoffgf pages 6-7, matsushita2009fgfr3promotessynchondrosis pages 1-2, huang2020enhancedfgfr3activity pages 12-14, huang2023exomesequencingin pages 1-2, huang2023exomesequencingin pages 9-10)

Category Term Ontology (ID) Mechanistic Note Key Evidence (citation IDs)
Gene/Protein FGFR3 HGNC:3689 FGFR3 K650E (p.Lys650Glu) is constitutively active, producing ligand-independent RTK signaling that drives growth-plate arrest and severe chondrodysplasia (chen2005rolesoffgf pages 4-6, hartl2022quantitationoffgfr3 pages 1-6, chen2005rolesoffgf pages 6-7)
Pathway STAT1 signaling GO:0042501 Activated FGFR3 upregulates STAT1 and cell-cycle inhibitors (eg. p21), mediating growth arrest/apoptosis in chondrocytes (chen2005rolesoffgf pages 6-7, chen2005rolesoffgf pages 4-6)
Pathway MAPK cascade GO:0000165 FGFR3 signals via RAS-RAF-MEK-ERK (MAPK) to inhibit chondrocyte differentiation and promote premature synchondrosis closure (matsushita2009fgfr3promotessynchondrosis pages 1-2, chen2005rolesoffgf pages 6-7, chen2005rolesoffgf pages 4-6)
Pathway PI3K/AKT signaling GO:0014065 FGFR3 recruits GRB2/GAB1 complexes that can engage PI3K–AKT, affecting cell survival and growth-plate responses (hartl2022quantitationoffgfr3 pages 1-6, chen2005rolesoffgf pages 6-7)
Pathway PLCγ signaling GO:0007205 FGFR3 activation can engage PLCγ to generate IP3/DAG signaling branches downstream of the receptor (hartl2022quantitationoffgfr3 pages 1-6)
Cell Type Growth plate chondrocyte CL:0000138 Primary effector cell type: FGFR3 activation narrows proliferative zone and disrupts columnar organization of chondrocytes (chen2005rolesoffgf pages 6-7, matsushita2009fgfr3promotessynchondrosis pages 1-2)
Cell Type Hypertrophic chondrocyte CL:0000135 Hypertrophic zone is reduced/disorganized in FGFR3 GOF, impairing endochondral maturation (chen2005rolesoffgf pages 6-7, matsushita2009fgfr3promotessynchondrosis pages 1-2)
Cell Type Cortical neuron CL:0002603 Neuronal FGFR3 GOF (K650E) perturbs cortical neuron migration/identity and axonal tract formation, causing cortical dysplasia (huang2020enhancedfgfr3activity pages 12-14)
Anatomical Long bone growth plate UBERON:0003860 Site of endochondral ossification where FGFR3 GOF reduces proliferation and shortens long bones (chen2005rolesoffgf pages 6-7)
Anatomical Cranial base synchondrosis UBERON:0006646 FGFR3–MAPK activity drives premature synchondrosis closure and ossification center fusion (matsushita2009fgfr3promotessynchondrosis pages 1-2)
Anatomical Foramen magnum UBERON:0010145 Premature cranial base fusion and altered growth can produce foramen magnum stenosis and neural compression (matsushita2009fgfr3promotessynchondrosis pages 1-2, chen2005rolesoffgf pages 6-7)
Anatomical Thoracic cage / rib UBERON:0002223 Impaired rib cage development and narrow thorax limit pulmonary expansion, contributing to perinatal respiratory failure (chen2005rolesoffgf pages 3-4, chen2005rolesoffgf pages 6-7)
Anatomical Cerebral cortex UBERON:0000956 FGFR3 GOF in cortical neurons leads to cortical lamination defects, heterotopia and axonal misrouting (huang2020enhancedfgfr3activity pages 12-14)
Process Endochondral ossification GO:0001958 FGFR3 GOF disrupts the coordinated proliferation–hypertrophy–ossification sequence underlying longitudinal bone growth (chen2005rolesoffgf pages 6-7, matsushita2009fgfr3promotessynchondrosis pages 1-2)
Process Chondrocyte proliferation GO:0033690 Constitutive FGFR3 signaling suppresses chondrocyte proliferation via STAT1/p21 and MAPK-mediated effects (chen2005rolesoffgf pages 6-7, chen2005rolesoffgf pages 4-6)
Process Chondrocyte differentiation GO:0002062 FGFR3 hyperactivity inhibits hypertrophic differentiation and alters extracellular matrix dynamics (chen2005rolesoffgf pages 6-7, matsushita2009fgfr3promotessynchondrosis pages 1-2)
Process Axon guidance GO:0007411 Neuronal FGFR3 GOF dysregulates axon guidance pathways (Slit-Robo, Wnt/Frizzled), contributing to tract abnormalities (huang2020enhancedfgfr3activity pages 12-14)
Phenotype Narrow thorax HP:0000774 Clinical consequence of thoracic hypoplasia that impairs respiration and contributes to perinatal lethality in TD-II (chen2005rolesoffgf pages 3-4, chen2005rolesoffgf pages 6-7)
Phenotype Foramen magnum stenosis HP:0005931 Result of premature cranial base fusion and synchondrosis closure driven by FGFR3–MAPK signaling (matsushita2009fgfr3promotessynchondrosis pages 1-2, chen2005rolesoffgf pages 6-7)
Phenotype Temporal lobe dysplasia / cortical dysplasia HP:0007340 Observed neuropathology (hippocampal/temporal dysplasia, heterotopia) in FGFR3 K650E-associated cases (huang2020enhancedfgfr3activity pages 12-14)
Phenotype Megalencephaly HP:0001355 FGFR3 GOF can associate with abnormal brain overgrowth/structural malformations in severe cases (huang2020enhancedfgfr3activity pages 12-14)
Chemical FGF1 CHEBI:30627 Ligand that activates FGFRs; experimental stimulation used to probe receptor responses and differential ligand effects (hartl2022quantitationoffgfr3 pages 1-6)
Chemical FGF2 CHEBI:31672 Potent FGFR ligand shown to modulate FGFR3 expression and influence growth-plate responses; used in experimental overexpression models (hartl2022quantitationoffgfr3 pages 1-6, chen2005rolesoffgf pages 6-7)

Table: A concise table mapping genes, pathways, cells, anatomical sites, processes, phenotypes, and chemicals implicated in Thanatophoric Dysplasia Type 2, with brief mechanistic notes and supporting evidence IDs for use in knowledge-base curation.

1. Core Pathophysiology

  • Causal event and receptor behavior: TD2 is classically caused by FGFR3 p.Lys650Glu (K650E), which “causes all cases of TD‑II” and yields stronger receptor activation than mutations underlying achondroplasia/hypochondroplasia; severity scales with activation level and expression dose. In mouse, the equivalent K644E allele is perinatal‑lethal (die within hours). “TD is the most common lethal neonatal skeletal disorder” with death “presumably as a result of extremely limited respiration caused by impaired thoracic cage development.” (Frontiers in Bioscience, 2005; URL: https://doi.org/10.2741/1671, published May 2005) (chen2005rolesoffgf pages 3-4, chen2005rolesoffgf pages 4-6)
  • Downstream pathways in chondrocytes: Activated FGFR3 recruits FRS2α/GRB2/SOS and GAB1 complexes to initiate RAS–RAF–MEK–ERK (MAPK) and PI3K–AKT; PLCγ/IP3/DAG are also engaged. Congenital FGFR3 mutants (including K650E) show elevated basal activity and ligand‑independent signaling at the plasma membrane. (bioRxiv preprint, 2022; URL: https://doi.org/10.1101/2022.04.11.487861, posted Apr 2022) (hartl2022quantitationoffgfr3 pages 1-6)
  • Cellular consequences in the growth plate: FGFR3 is a negative regulator of endochondral bone growth; gain‑of‑function reduces chondrocyte proliferation and narrows disorganized proliferative and hypertrophic zones. Mechanistically, FGFR3 activation upregulates STAT1 and cell‑cycle inhibitors (p21 and related CKIs) leading to growth arrest/apoptosis, while ERK/MAPK inhibits hypertrophic differentiation; FGFR3 also downregulates IHH and PTHrP‑R signaling in parallel. (Frontiers in Bioscience, 2005; URL: https://doi.org/10.2741/1671, published May 2005) (chen2005rolesoffgf pages 6-7)
  • Synchondrosis closure and cranial base: Chondrocyte‑specific FGFR3‑MAPK activation promotes premature synchondrosis closure and fusion of ossification centers, with MAPK‑dependent increases in Bmp ligand expression and decreases in antagonists, explaining foramen magnum stenosis and early spinal canal narrowing in severe FGFR3 dysplasias. (Human Molecular Genetics, 2009; URL: https://doi.org/10.1093/hmg/ddn339, published Oct 2009) (matsushita2009fgfr3promotessynchondrosis pages 1-2)
  • Brain malformations: FGFR3 K650E produces constitutive kinase activity; FGFR3 gain‑of‑function in post‑mitotic glutamatergic neurons disrupts RGC mitosis, radial migration, neuronal identity, and axonal tract formation with RNA‑seq showing dysregulated axon guidance (Slit/Robo, Wnt/Frizzled). Neuropathology in FGFR3 GOF human cases includes hippocampal dysplasia, heterotopia, and cortical lamination defects. (Scientific Reports, 2020; URL: https://doi.org/10.1038/s41598-020-75537-0, published Oct 2020) (huang2020enhancedfgfr3activity pages 12-14)

2. Key Molecular Players

  • Genes/Proteins (HGNC): FGFR3 (HGNC:3689) is the causal gene; K650E is the canonical TD2 allele, with stronger activation than G380R (achondroplasia) and N540K (hypochondroplasia). Impaired receptor downregulation (e.g., reduced c‑Cbl–mediated ubiquitination) contributes to sustained signaling in some FGFR3 GOF contexts. (Frontiers in Bioscience, 2005; URL: https://doi.org/10.2741/1671, May 2005) (chen2005rolesoffgf pages 4-6)
  • Signaling nodes: STAT1 and CDK inhibitors (p21/others) mediate proliferation arrest; RAS–RAF–MEK–ERK suppresses hypertrophic differentiation; PI3K–AKT and PLCγ branches contribute to broader survival and transcriptional programs. (Frontiers in Bioscience, 2005; bioRxiv 2022; URLs above) (chen2005rolesoffgf pages 6-7, hartl2022quantitationoffgfr3 pages 1-6)
  • Chemical entities (CHEBI): FGF1 and FGF2 experimental ligands modulate FGFR3; elevated FGFR liganding and overexpression models phenocopy GOF effects on cartilage. (bioRxiv 2022; Frontiers in Bioscience 2005; URLs above) (hartl2022quantitationoffgfr3 pages 1-6, chen2005rolesoffgf pages 6-7)
  • Cell types (CL): Growth‑plate chondrocytes (resting/proliferative/pre‑hypertrophic/hypertrophic) are primary effectors; post‑mitotic cortical neurons are affected in brain. (Frontiers in Bioscience 2005; Sci Rep 2020) (chen2005rolesoffgf pages 6-7, huang2020enhancedfgfr3activity pages 12-14)
  • Anatomical locations (UBERON): Long bone growth plate; cranial base synchondroses and foramen magnum; ribs/thoracic cage; cerebral cortex. (HMG 2009; Frontiers in Bioscience 2005; Sci Rep 2020) (matsushita2009fgfr3promotessynchondrosis pages 1-2, chen2005rolesoffgf pages 6-7, huang2020enhancedfgfr3activity pages 12-14)

3. Biological Processes (GO terms)

  • Negative regulation of chondrocyte proliferation via STAT1/p21 and related CKIs; inhibition of chondrocyte hypertrophic differentiation via MAPK; disruption of endochondral ossification program. (Frontiers in Bioscience 2005) (chen2005rolesoffgf pages 6-7)
  • Positive regulation of BMP output in chondrocytes (via MAPK) at synchondroses, accelerating ossification center fusion. (HMG 2009) (matsushita2009fgfr3promotessynchondrosis pages 1-2)
  • Axon guidance signaling perturbations (Slit/Robo, Wnt/Frizzled) and altered neuronal identity programs in cortex. (Sci Rep 2020) (huang2020enhancedfgfr3activity pages 12-14)
  • Receptor tyrosine kinase signaling at the plasma membrane through FRS2/GRB2/SOS and GAB1 scaffolds; PI3K–AKT, PLCγ/IP3–DAG branches. (bioRxiv 2022) (hartl2022quantitationoffgfr3 pages 1-6)

4. Cellular Components

  • Plasma membrane: FGFR3 dimerization and trans‑autophosphorylation with docking for FRS2α, GRB2, SHP2, PLCγ; surface signaling may differ from bulk cell extract readouts. (bioRxiv 2022) (hartl2022quantitationoffgfr3 pages 1-6)
  • Cytosol: RAS–RAF–MEK–ERK and PI3K–AKT cascades; PLCγ‑mediated second messengers. (bioRxiv 2022) (hartl2022quantitationoffgfr3 pages 1-6)
  • Nucleus: STAT1‑dependent transcriptional repression of proliferation via p21 and other CKIs; altered chondrocyte differentiation gene programs. (Frontiers in Bioscience 2005) (chen2005rolesoffgf pages 6-7)

5. Disease Progression (Sequence of Events)

1) De novo FGFR3 K650E occurs in the embryo, encoding a kinase‑domain change that “causes constitutive activation of FGFR3,” stronger than ACH/HCH variants. (Frontiers in Bioscience 2005) (chen2005rolesoffgf pages 3-4) 2) Constitutive RTK signaling engages STAT1/p21‑mediated proliferation arrest and ERK/MAPK‑mediated blockade of hypertrophic differentiation in growth‑plate chondrocytes; growth plate zones narrow and disorganize. (Frontiers in Bioscience 2005) (chen2005rolesoffgf pages 6-7) 3) MAPK‑dependent shift toward BMP ligand expression in synchondroses accelerates cranial base fusion; foramen magnum stenosis/spinal canal narrowing emerge early. (HMG 2009) (matsushita2009fgfr3promotessynchondrosis pages 1-2) 4) Systemically, endochondral ossification fails: long bones are markedly shortened, ribs/thorax remain hypoplastic, cranial vault is large with midface hypoplasia. (Frontiers in Bioscience 2005) (chen2005rolesoffgf pages 3-4) 5) In the brain, FGFR3 GOF disrupts neurogenesis/migration/axon guidance, producing temporal/cortical dysplasia and heterotopia that are characteristic in severe FGFR3 disorders. (Sci Rep 2020) (huang2020enhancedfgfr3activity pages 12-14) 6) Prenatal ultrasound recognizes a narrow thorax and severe limb shortening; perinatal lethality results primarily from respiratory insufficiency due to thoracic hypoplasia. (Frontiers in Bioscience 2005; 2024 ultrasound review) (chen2005rolesoffgf pages 3-4, ward2024skeletaldysplasias pages 1-2)

6. Phenotypic Manifestations (HP terms)

  • Severe micromelia and extremely short limbs; narrow thorax leading to respiratory failure; macrocephaly with frontal bossing; foramen magnum stenosis; cortical/temporal lobe dysplasia and heterotopia in some cases. Representative statement: “TD is the most common lethal neonatal skeletal disorder,” with lethality due to impaired thoracic cage development; TD2 is associated with K650E. (Frontiers in Bioscience 2005; 2024 ultrasound review) (chen2005rolesoffgf pages 3-4, ward2024skeletaldysplasias pages 1-2)

7. Recent Developments (2023–2024) and Applications

  • Prenatal genomics for fetuses with short long bones:
  • In a 2023 trio‑exome cohort (n=94 SLB fetuses), overall diagnostic yield was 40.4%; skeletal dysplasias comprised 37.2% of all cases; FGFR3 accounted for 42.1% of molecular diagnoses. Thanatophoric dysplasia comprised 10.5% of diagnoses. Severity correlated strongly with yield: 72.5% when femur length < −4 SD vs 16.7% for −2 to −4 SD (p<0.001). Authors concluded that ES adds clinically relevant information for counseling and management. (Frontiers in Genetics, 2023; URL: https://doi.org/10.3389/fgene.2023.1032346, published Feb 2023) (huang2023exomesequencingin pages 1-2, huang2023exomesequencingin pages 9-10)
  • A 2023 prenatal WES series (n=145) reported an overall trio WES diagnostic rate of 28.1% and the highest yield in musculoskeletal anomalies (51.4%). FGFR3 and COL1A1 were the most common pathogenic genes detected, guiding prognosis and parental decision‑making. (BMC Medical Genomics, 2023; URL: https://doi.org/10.1186/s12920-023-01697-3, published Oct 2023) (qin2023prenatalwholeexomesequencing pages 1-2)
  • Ultrasound review (2024) lists TD incidence near 1/20,000 and summarizes TD1 vs TD2 features (TD2 with straight femora and severe craniosynostosis), noting that ultrasound correctly assigns skeletal dysplasia subtypes in ~60–65% of cases antenatally. (Donald School J Ultrasound Obstet Gynecol, 2024; URL: https://doi.org/10.5005/jp-journals-10009-2023, published Jun 2024) (ward2024skeletaldysplasias pages 1-2)
  • Mechanistic clarifications and models:
  • Quantitative live‑cell readouts (2022) demonstrate ligand‑independent activation for multiple FGFR3 mutants including K650E and map pathway engagement (RAS/MAPK, PI3K/AKT, PLCγ) at the plasma membrane, informing drug‑target engagement strategies. (bioRxiv, 2022; URL above) (hartl2022quantitationoffgfr3 pages 1-6)
  • Synchondrosis mechanism (MAPK→BMP) provides a window for timing‑dependent interventions prior to cranial base fusion. (HMG, 2009; URL above) (matsushita2009fgfr3promotessynchondrosis pages 1-2)
  • Real‑world implementations: Prenatal ES/WES is being integrated after CMA in fetuses with SLB to detect de novo FGFR3 variants, with results materially influencing decisions and perinatal planning; diagnostic rates are highest in severe shortening and multiple anomalies, highlighting selection criteria for testing. (Frontiers in Genetics 2023; BMC Med Genomics 2023) (huang2023exomesequencingin pages 1-2, qin2023prenatalwholeexomesequencing pages 1-2)

8. Expert Opinions and Authoritative Analyses

  • Foundational review (Chen & Deng) synthesizes that FGFR3 is a negative regulator of bone growth and that “there is a correlation between the degree of receptor activation and the severity of the dwarfism phenotype,” explicitly associating K650E with TD2 and perinatal lethality due to thoracic hypoplasia. (Frontiers in Bioscience, 2005; URL above) (chen2005rolesoffgf pages 3-4, chen2005rolesoffgf pages 4-6)
  • Mechanistic paper (Matsushita et al.) emphasizes that FGFR3–MAPK in chondrocytes drives premature synchondrosis closure via BMP modulation, directly linking pathway biology to foramen magnum stenosis and timing‑sensitive windows for intervention. (HMG, 2009; URL above) (matsushita2009fgfr3promotessynchondrosis pages 1-2)
  • Neuroscience model (Huang et al.) demonstrates that FGFR3 K650E in neurons is sufficient to produce cortical dysplasia and axonal tract defects, supporting the attribution of TD2 brain malformations to receptor hyperactivation. (Sci Rep, 2020; URL above) (huang2020enhancedfgfr3activity pages 12-14)

9. Relevant Statistics and Data

  • TD incidence: approximately 1 in 20,000 births; TD contributes ~29% of lethal skeletal dysplasias in some ultrasound series. (2024 ultrasound review; URL: https://doi.org/10.5005/jp-journals-10009-2023) (ward2024skeletaldysplasias pages 1-2)
  • Prenatal ES in SLB fetuses (n=94): 40.4% molecular diagnosis; FGFR3 causes 42.1% of positive diagnoses, with TD ~10.5% of cases; diagnostic yield 72.5% (FL < −4 SD) vs 16.7% (−2 to −4 SD). (Frontiers in Genetics, 2023; URL: https://doi.org/10.3389/fgene.2023.1032346) (huang2023exomesequencingin pages 1-2, huang2023exomesequencingin pages 9-10)
  • Prenatal WES (n=145): overall trio yield 28.1%; musculoskeletal anomalies 51.4% yield; FGFR3 among top causal genes. (BMC Med Genomics, 2023; URL: https://doi.org/10.1186/s12920-023-01697-3) (qin2023prenatalwholeexomesequencing pages 1-2)

10. Structured Annotations for Knowledge Base

  • Gene/protein (HGNC): FGFR3 (HGNC:3689). Evidence: GOF K650E causes TD2; activation severity correlates with phenotype. (Frontiers in Bioscience 2005; URL above) (chen2005rolesoffgf pages 3-4, chen2005rolesoffgf pages 4-6)
  • Biological processes (GO): negative regulation of chondrocyte proliferation via STAT1/p21; MAPK cascade; endochondral ossification; axon guidance in cortex. (Frontiers in Bioscience 2005; HMG 2009; Sci Rep 2020) (chen2005rolesoffgf pages 6-7, matsushita2009fgfr3promotessynchondrosis pages 1-2, huang2020enhancedfgfr3activity pages 12-14)
  • Cellular components: plasma membrane FGFR3 complex (FRS2/GRB2/SOS, GAB1), cytosolic ERK and AKT cascades, nuclear STAT1 transcription. (bioRxiv 2022; Frontiers in Bioscience 2005) (hartl2022quantitationoffgfr3 pages 1-6, chen2005rolesoffgf pages 6-7)
  • Phenotypes (HP): HP:0000774 Narrow thorax; HP:0005931 Foramen magnum stenosis; HP:0007340 Cortical/temporal lobe dysplasia; HP:0001355 Megalencephaly. (Frontiers in Bioscience 2005; HMG 2009; Sci Rep 2020) (chen2005rolesoffgf pages 3-4, matsushita2009fgfr3promotessynchondrosis pages 1-2, huang2020enhancedfgfr3activity pages 12-14)
  • Cell types (CL): CL:0000138 growth‑plate chondrocyte; CL:0000135 hypertrophic chondrocyte; CL:0002603 cortical neuron. (Frontiers in Bioscience 2005; Sci Rep 2020) (chen2005rolesoffgf pages 6-7, huang2020enhancedfgfr3activity pages 12-14)
  • Anatomical (UBERON): UBERON:0003860 growth plate; UBERON:0006646 cranial base synchondrosis; UBERON:0010145 foramen magnum; UBERON:0002223 rib/thoracic cage; UBERON:0000956 cerebral cortex. (HMG 2009; Frontiers in Bioscience 2005; Sci Rep 2020) (matsushita2009fgfr3promotessynchondrosis pages 1-2, chen2005rolesoffgf pages 6-7, huang2020enhancedfgfr3activity pages 12-14)
  • Chemicals (CHEBI): CHEBI:30627 FGF1; CHEBI:31672 FGF2. (bioRxiv 2022; Frontiers in Bioscience 2005) (hartl2022quantitationoffgfr3 pages 1-6, chen2005rolesoffgf pages 6-7)

11. Direct Quotes Supporting Key Statements

  • “K650E mutation causes all cases of TD‑II.” and “TD is the most common lethal neonatal skeletal disorder… [lethality] as a result of extremely limited respiration caused by impaired thoracic cage development.” (Frontiers in Bioscience, 2005; URL: https://doi.org/10.2741/1671) (chen2005rolesoffgf pages 3-4)
  • “Among these [FGFR3 substitutions], the degree of receptor activation correlates with the severity of dwarfism… mice carrying K644E (equivalent to human K650E) show most severe phenotypes, and die within few hours after birth.” (Frontiers in Bioscience, 2005; URL above) (chen2005rolesoffgf pages 4-6)
  • “FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway,” with increased Bmp ligands and decreased antagonists in chondrocytes. (Human Molecular Genetics, 2009; URL: https://doi.org/10.1093/hmg/ddn339) (matsushita2009fgfr3promotessynchondrosis pages 1-2)
  • “Gain‑of‑function in FGFR3… causes constitutive activation of FGFR3 tyrosine kinase,” and mouse neuronal GOF disrupts radial migration and axonal tracts; RNA‑seq shows altered axon guidance. (Scientific Reports, 2020; URL: https://doi.org/10.1038/s41598-020-75537-0) (huang2020enhancedfgfr3activity pages 12-14)

12. Clinical and Translational Implications

  • Diagnosis: In fetuses with short long bones, trio‑exome sequencing after normal karyotype/CMA yields high diagnostic rates, especially with severe shortening (FL < −4 SD). FGFR3 variants (including TD) are frequent and should be prioritized in targeted panels; ultrasound recognition remains essential but is imperfect for precise subtyping. (Frontiers in Genetics 2023; BMC Med Genomics 2023; 2024 ultrasound review) (huang2023exomesequencingin pages 1-2, qin2023prenatalwholeexomesequencing pages 1-2, ward2024skeletaldysplasias pages 1-2)
  • Management: Recognizing TD2’s respiratory lethality is critical for perinatal planning. Premature cranial base fusion suggests early surveillance for foramen magnum stenosis in survivors/variant phenotypes. Timing of any hypothetical growth‑promoting or FGFR3‑modulating interventions would need to precede synchondrosis closure. (HMG 2009) (matsushita2009fgfr3promotessynchondrosis pages 1-2)
  • Therapeutic research landscape: While disease‑modifying agents are established for achondroplasia, the mechanistic insights relevant to FGFR3 signaling branches (STAT1/p21; MAPK; PI3K/AKT; PLCγ) and plasma‑membrane activation state reinforce targets for future pathway modulation in FGFR3 chondrodysplasias; however, TD2’s lethality and early onset impose substantial translational barriers. (bioRxiv 2022; Frontiers in Bioscience 2005) (hartl2022quantitationoffgfr3 pages 1-6, chen2005rolesoffgf pages 6-7)

References (URLs and dates embedded above).

References

  1. (chen2005rolesoffgf pages 3-4): Lin Chen and C. Deng. Roles of fgf signaling in skeletal development and human genetic diseases. Frontiers in bioscience : a journal and virtual library, 10:1961-76, May 2005. URL: https://doi.org/10.2741/1671, doi:10.2741/1671. This article has 130 citations.

  2. (chen2005rolesoffgf pages 6-7): Lin Chen and C. Deng. Roles of fgf signaling in skeletal development and human genetic diseases. Frontiers in bioscience : a journal and virtual library, 10:1961-76, May 2005. URL: https://doi.org/10.2741/1671, doi:10.2741/1671. This article has 130 citations.

  3. (matsushita2009fgfr3promotessynchondrosis pages 1-2): T. Matsushita, W. R. Wilcox, Y. Y. Chan, A. Kawanami, H. Bukulmez, G. Balmes, P. Krejci, P. B. Mekikian, K. Otani, I. Yamaura, M. L. Warman, D. Givol, and S. Murakami. Fgfr3 promotes synchondrosis closure and fusion of ossification centers through the mapk pathway. Human Molecular Genetics, 18:227-240, Oct 2009. URL: https://doi.org/10.1093/hmg/ddn339, doi:10.1093/hmg/ddn339. This article has 165 citations and is from a domain leading peer-reviewed journal.

  4. (huang2020enhancedfgfr3activity pages 12-14): Jui-Yen Huang, Bruna Baumgarten Krebs, Marisha Lynn Miskus, May Lin Russell, Eamonn Patrick Duffy, Jason Michael Graf, and Hui-Chen Lu. Enhanced fgfr3 activity in postmitotic principal neurons during brain development results in cortical dysplasia and axonal tract abnormality. Scientific Reports, Oct 2020. URL: https://doi.org/10.1038/s41598-020-75537-0, doi:10.1038/s41598-020-75537-0. This article has 15 citations and is from a peer-reviewed journal.

  5. (huang2023exomesequencingin pages 1-2): Yanlin Huang, Chang Liu, Hongke Ding, Yu-nan Wang, Lihua Yu, Fang-Fang Guo, Fake Li, Xiaomei Shi, Yan Zhang, and A-Q. Yin. Exome sequencing in fetuses with short long bones detected by ultrasonography: a retrospective cohort study. Frontiers in Genetics, Feb 2023. URL: https://doi.org/10.3389/fgene.2023.1032346, doi:10.3389/fgene.2023.1032346. This article has 21 citations and is from a peer-reviewed journal.

  6. (huang2023exomesequencingin pages 9-10): Yanlin Huang, Chang Liu, Hongke Ding, Yu-nan Wang, Lihua Yu, Fang-Fang Guo, Fake Li, Xiaomei Shi, Yan Zhang, and A-Q. Yin. Exome sequencing in fetuses with short long bones detected by ultrasonography: a retrospective cohort study. Frontiers in Genetics, Feb 2023. URL: https://doi.org/10.3389/fgene.2023.1032346, doi:10.3389/fgene.2023.1032346. This article has 21 citations and is from a peer-reviewed journal.

  7. (chen2005rolesoffgf pages 4-6): Lin Chen and C. Deng. Roles of fgf signaling in skeletal development and human genetic diseases. Frontiers in bioscience : a journal and virtual library, 10:1961-76, May 2005. URL: https://doi.org/10.2741/1671, doi:10.2741/1671. This article has 130 citations.

  8. (hartl2022quantitationoffgfr3 pages 1-6): Ingrid Hartl, Veronika Brumovska, Yasmin Striedner, Atena Yasari, Gerhard J. Schütz, Eva Sevcsik, and Irene Tiemann-Boege. Quantitation of fgfr3 signaling via grb2 recruitment on micropatterned surfaces. bioRxiv, Apr 2022. URL: https://doi.org/10.1101/2022.04.11.487861, doi:10.1101/2022.04.11.487861. This article has 2 citations and is from a poor quality or predatory journal.

  9. (ward2024skeletaldysplasias pages 1-2): Kenneth Ward and Pamela Grant. Skeletal dysplasias. Donald School Journal of Ultrasound in Obstetrics and Gynecology, 18:171-175, Jun 2024. URL: https://doi.org/10.5005/jp-journals-10009-2023, doi:10.5005/jp-journals-10009-2023. This article has 0 citations and is from a poor quality or predatory journal.

  10. (qin2023prenatalwholeexomesequencing pages 1-2): Yayun Qin, Yanyi Yao, Nian Liu, Bo Wang, Lijun Liu, Hui Li, Tangxinzi Gao, Runhong Xu, Xiaoyan Wang, Fanglian Zhang, and Jieping Song. Prenatal whole-exome sequencing for fetal structural anomalies: a retrospective analysis of 145 chinese cases. BMC Medical Genomics, Oct 2023. URL: https://doi.org/10.1186/s12920-023-01697-3, doi:10.1186/s12920-023-01697-3. This article has 24 citations and is from a peer-reviewed journal.